Document:

Form of Employee Matters Agreement

 Exhibit 10.5 
 FORM OF 
 EMPLOYEE MATTERS AGREEMENT 

This EMPLOYEE MATTERS AGREEMENT (this “Agreement”) dated as of [—],
201[—], is by and among PFIZER INC., a Delaware corporation (“Pfizer”) and ZOETIS INC., a Delaware corporation (the “Company”). Pfizer and the Company are sometimes
referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS:

 WHEREAS, the Board of Directors of Pfizer has determined that it is in the best interests of Pfizer and its stockholders to
separate the Animal Health Business (as such term is defined in the Global Separation Agreement, dated as of the date hereof (the “Separation Agreement”)) from the other businesses conducted by Pfizer and its Subsidiaries (as
defined in the Separation Agreement); 
 WHEREAS, the Parties have entered into that certain Contribution Agreement, dated as of
[—] (the “Contribution Agreement”) pursuant to which Pfizer and its Subsidiaries transferred the capital stock and equity interests of the Transferred Entities (as defined in the
Separation Agreement) to the Company in exchange for the Company’s issuance to Pfizer of Company common stock and certain securities and the Company’s payment to Pfizer of cash, as more fully described in the Contribution Agreement;

 WHEREAS, the Separation Agreement sets forth the terms and conditions applicable to the IPO (as defined in the Separation
Agreement); 
 WHEREAS, after the IPO, Pfizer may determine to proceed with the Distribution or Other Disposition (each, as
defined in the Separation Agreement); and 
 WHEREAS, in furtherance of the foregoing, the Parties have entered into this
Agreement, which is an Ancillary Agreement (as defined in the Separation Agreement) to the Separation Agreement, to govern the rights and obligations of the Parties with respect to employment, compensation, employee benefits and related matters in
connection with the Transactions (as defined in the Separation Agreement), and to ratify actions previously taken in connection with the Contribution (as defined in the Separation Agreement), as set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and the covenants and agreements set forth below, the parties hereto agree as follows:

 ARTICLE I 
 SCOPE OF AGREEMENT; DEFINITIONS 
 Capitalized terms used but not defined
herein shall have the meaning ascribed to them in the Separation Agreement. For purposes of this Agreement the terms set forth below shall have the following meanings: 
 1.1 Company Deferred Compensation Plan shall have the meaning set forth in Subsection 7.1(c)(ii). 

  
 1 

 1.2 Company Employee means any individual who is (i) employed by Pfizer or a
Subsidiary immediately prior to the applicable Employee Transfer Date and primarily devoting his or her working time to the Animal Health Business (excluding each R&D Employee) or (ii) employed by the Company immediately following the
applicable Employee Transfer Date. 
 1.4 Company Flexible Benefits Plans means the Company Health Care Spending Account
Plan and the Company Dependent Care Spending Account Plan to be established by the Company pursuant to Section 3.2 to accept a spin-off of the flexible spending reimbursement accounts of Company Transferred Employees under the respective Pfizer
Flexible Spending Account Plans in accordance with Section 8.4. 
 1.5 Company Group means the Company, each
Transferred Entity, each other Subsidiary of the Company and each other Person that either (i) is controlled directly or indirectly by the Company immediately after the Effective Date or (ii) becomes controlled by the Company following the
Effective Date. 
 1.6 Company Supplemental Savings Plan shall have the meaning set forth in Subsection 7.1(b)(ii).

 1.7 Company Transferred Employee means any Company Employee (i) whose employment transferred from a member of the
Pfizer Group to a member of the Company Group by operation of law or (ii) who accepted an offer of employment from a member of the Company Group, in each case as of the applicable Employee Transfer Date; provided, however, that any Company
Employee receiving long-term disability benefits shall not transfer and shall remain employed by a member of the Pfizer Group unless otherwise required by applicable Law, and provided, further, that any Inactive Company Employee shall become a
Company Transferred Employee on such employee’s Return Date and until such time shall remain employed by a member of the Pfizer Group. 
 1.8 Company WC Claims shall have the meaning set forth in Subsection 8.8(b)(i). 
 1.9 COBRA means the continuation coverage requirements for “group health plans” under Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended from time to
time, and as codified in Code Section 4980B and ERISA Sections 601 through 608. 
 1.10 Disposition Date means
the earlier to occur of the Distribution or Other Disposition such that Pfizer and its Affiliates cease to hold in excess of 50% of the outstanding shares of Company common stock. 

1.11 DOL means the United States Department of Labor. 
 1.12 Employee Transfer Date means the date by which Company Employees will have transferred or accepted offers of employment from a member of the Company Group; for U.S. employees, this date is
October 1, 2012 or such other date that a Pfizer Employee is offered employment by the Company and transfers employment to the Company, and for non-U.S. employees this date is December 1, 2012, or such other date as agreed upon by the
Parties in respect of specified jurisdictions. 

  
 2 

 1.13 Effective Date has the meaning set forth in the Separation Agreement.

 1.14 ERISA means the Employee Retirement Income Security Act of 1974, as amended from time to time. 

1.15 Final Determination means the final resolution of liability for any tax, which resolution may be for a specific issue or
adjustment or for a taxable period, (i) by IRS Form 870 or 870-AD (or any successor forms thereto), on the date of acceptance by or on behalf of the taxpayer, or by a comparable form under the laws of a state, local, or foreign taxing
jurisdiction, except that a Form 870 or 870-AD or comparable form shall not constitute a Final Determination to the extent that it reserves (whether by its terms or by operation of law) the right of the taxpayer to file a claim for refund or the
right of the tax authority to assert a further deficiency in respect of such issue or adjustment or for such taxable period (as the case may be); (ii) by a decision, judgment, decree, or other order by a court of competent jurisdiction, which
has become final and unappealable; (iii) by a closing agreement or accepted offer in compromise under Sections 7121 or 7122 of the Internal Revenue Code, or a comparable agreement under the laws of a state, local, or foreign taxing
jurisdiction. 
 1.16 FMLA means the Family and Medical Leave Act of 1993, as amended from time to time. 

1.17 Former Company Employee means any individual (i) whose employment with Pfizer and its Subsidiaries terminated prior to
the Employee Transfer Date and who was, immediately prior to such termination, primarily devoting his or her working time to the Animal Health Business, or (ii) is designated as a Former Company Employee on Exhibit B hereto. 

1.18 Fringe Benefits means, when immediately preceded by “Pfizer,” the Pfizer or legacy King Pharmaceuticals, Inc.
employee assistance program, the educational assistance program and other fringe benefits, plans, programs and arrangements sponsored and maintained by Pfizer and, when immediately preceded by “Company,” any fringe benefits, plans,
programs and arrangements to be established by the Company. 
 1.19 Health and Welfare Plans means, when immediately
preceded by “Pfizer,” the Pfizer or King Pharmaceuticals, Inc. health plans, the Pfizer Health and Insurance Program , and the other health and welfare plans established and maintained by Pfizer or a Subsidiary and, when immediately
preceded by “Company,” the Company Health Plans, the Company Flexible Benefits Plans, and the other health and welfare plans to be established by the Company pursuant to Section 3.2. 

1.20 Health Plans means, when immediately preceded by “Pfizer,” the group health plans and such other health plans or
programs, including medical, prescription drug, dental and vision plans and programs established and maintained by Pfizer or a Subsidiary and, when immediately preceded by “Company,” the health plans, programs and arrangements to be
established by the Company pursuant to Section 3.2. 

  
 3 

 1.21 Inactive Company Employee means any Company Employee and who is not actively at
work on the Employee Transfer Date because he or she is on approved short-term disability or other approved leave in accordance (excluding long-term disability) with the applicable Pfizer Leave of Absence Program. 

1.22 Leave of Absence Programs means, when immediately preceded by “Pfizer,” the personal, medical, military and FMLA
leave and other leaves of absence required by applicable Law or offered from time to time under the personnel policies and practices of Pfizer and when immediately preceded by “Company,” the leave of absence programs to be established by
the Company pursuant to Section 3.2 that correspond to the respective Pfizer Leave of Absence Program. 
 1.23 Legacy
Defined Benefit Plan means the Alpharma Inc., Pension Plan and the Faulding Inc. Pension Plan. 
 1.24 Legacy Retiree
Medical Plan means the Alpharma Retiree Medical Plan. 
 1.25 Legacy Savings Plan means the King Pharmaceuticals
Inc., 401(k) Savings Plan. 
 1.26 Legacy SERP means the Supplemental Executive Retirement Plan, the Warner Lambert
Supplemental Pension Income Plan, and the Pharmacia, Corp. Supplemental Pension Plan. 
 1.27 Life Insurance Plan means,
when immediately preceded by “Pfizer,” the life insurance plan of Pfizer and any similar legacy King Pharmaceuticals, Inc. plan, and when immediately preceded by “Company,” the life insurance plan to be established by the Company
pursuant to Section 3.2 that corresponds to the respective Pfizer Life Insurance Plan. 
 1.28 Local Separation
Agreement has the meaning set forth in the Separation Agreement. 
 1.29 Long-Term Disability Plan means, when
immediately preceded by “Pfizer,” the Pfizer Long-Term Disability Plan or any similar legacy King Pharmaceuticals, Inc. plan and when immediately preceded by “Company,” the long-term disability plan to be established by the
Company pursuant to Section 3.2. 
 1.30 Nonqualified Plans means when immediately preceded by “Pfizer,”
the Nonfunded Deferred Compensation and Supplemental Savings Plan, the Nonfunded Supplemental Retirement Plan, the Deferred Compensation Plan, and the Wyeth Plans, and, when immediately preceded by “Company,” the Supplemental Savings Plan
to be established by the Company pursuant to Sections 3.2 and 7.1. 
 1.31 Option means an option to purchase Pfizer
common stock pursuant to the Pfizer Stock Plan. 
 1.32 Participating Company means, with respect to any Plan:
(i) any Person (other than an individual) that Pfizer has approved for participation in, has accepted participation in, and which is participating in, a Plan sponsored by Pfizer; or (ii) any Person (other than an individual) which, by the
terms of such Plan, participates in such Plan or any employees of which, by the terms of such Plan, participate in or are covered by such Plan. 

  
 4 

 1.33 Pfizer Employee means an employee other than a Company Employee who, on the
Employee Transfer Date, is: (i) either actively employed by, or on leave of absence from, any member of the Pfizer Group or (ii) an R&D Employee. 
 1.34 Pfizer Flexible Benefits Plans means the Pfizer Health Care Spending Account Plan and the Pfizer Dependent Care Spending Account Plan and the King Pharmaceuticals, Inc. flexible spending
plans. 
 1.35 Pfizer Group means Pfizer, each other Subsidiary of Pfizer involved in the Transactions and each other
Person that either (x) is controlled directly or indirectly by Pfizer immediately after the Effective Date or (y) becomes controlled by Pfizer following the Effective Date; provided, however, that neither the Company nor any other member
of the Company Group shall be members of the Pfizer Group. 
 1.36 Pfizer Retirement Plan means the Pfizer Consolidated
Pension Plan. 
 1.37 Pfizer Stock Plan means the Pfizer Inc. 2004 Stock Plan, any other plan, program or arrangement,
pursuant to which employees and other service providers hold Options, Restricted Stock Units or other Pfizer equity incentives. 

1.38 Plan means any written or unwritten plan, policy, program, payroll practice, arrangement, contract, trust, insurance policy,
or any agreement or funding vehicle providing compensation or benefits to employees, former employees or directors of a member of the Pfizer Group or the Company Group; when immediately preceded by “Pfizer,” the Pfizer Plans and when
immediately preceded by “Company,” the plans to be established by the Company. 
 1.39 Plan Transition Date
means, except as agreed upon by the Parties in respect of specified jurisdictions, the date that is the earlier to occur of (i) the date that the Company is no longer a member of the “controlled group” of corporations of Pfizer (as
defined in Section 414(b) of the Code) or (ii) the date, which Pfizer and the Company shall mutually agree in writing upon which the Company shall cease to be a Participating Company in the Pfizer Plans and shall establish the Company
Plans, as set forth herein. 
 1.40 PSA means a “Performance Share Award,” which is an award to receive shares
of Pfizer common stock that is subject to corporate performance criteria, issued pursuant to the Pfizer Stock Plan. 
 1.41
QDRO means a domestic relations order which qualifies under Section 414(p) of the Code and ERISA Section 206(d) and which creates or recognizes an alternate payee’s right to, or assigns to an alternate payee, all or a portion
of the benefits payable to a participant under a plan qualified under Section 401(a) of the Code. 
 1.42 QMCSO
means a medical child support order which qualifies under ERISA Section 609(a) and which creates or recognizes the existence of an alternate recipient’s right to, or assigns to an alternate recipient the right to, receive benefits for
which a participant or beneficiary is eligible under any of the Health Plans. 

  
 5 

 1.43 R&D Employee means any individual designated as a “Curator” in the
Research and Development Collaboration and License Agreement, pursuant to which such individual is employed by Pfizer and who will provide services to a member of the Company Group. 

1.44 Restricted Stock Unit means a contractual right to receive shares of Pfizer common stock or the cash value thereof, which
right is subject to transfer restrictions or to employment and/or performance vesting conditions, issued pursuant to the Pfizer Stock Plan. 
 1.45 Retiree Programs means the Pfizer Retiree Medical Plan, and the Legacy Retiree Medical Plan. 
 1.46 Return Date means the date on which an Inactive Company Employee returns to active employment. 
 1.47 Savings Plan means when immediately preceded by “Pfizer,” means the Pfizer Savings Plan, a defined contribution plan and when immediately preceded by “Company,” means the
defined contribution plan funded by a trust that is qualified under Code Section 401(a) and exempt from taxation under Code Section 501(a)(1), to be established by the Company pursuant to Section 3.2 and Article 6. 

1.48 Separation Agreement has the meaning set forth in the recitals. 

1.49 Short-Term Disability Plan means when immediately preceded by “Pfizer,” the Pfizer Short-Term Disability policy or
any similar legacy King Pharmaceuticals, Inc. plan or policy (or, where an employee works in a state that offers a statutory state short-term disability plan, then “Short-Term Disability Plan” refers to the alternative voluntary state
disability plan offered under the Short-Term Disability Plan) and when immediately preceded by “Company,” means the short-term disability plan to be established by the Company pursuant to Section 3.2. 

1.50 TSRU means a “Total Shareholder Return Unit,” which is a contractual right to receive an award of shares of Pfizer
common stock with a value equal to the change in the stock price of Pfizer common stock over the applicable settlement period, as well as accrued dividend equivalents, subject to certain restrictions and issued pursuant to the Pfizer Stock Plan.

 1.51 Wyeth Plans means the Wyeth Deferred Compensation Plan, the Wyeth Supplemental Executive Retirement Plan and the
Wyeth Supplemental Employee Savings Plan. 
 ARTICLE II 
 GLOBAL PROVISION; GENERAL ALLOCATION OF LIABILITIES 
 2.1 In
General. All provisions herein shall be subject to the requirements of all applicable Law and any collective bargaining, works council or similar agreement or arrangement with any labor union. The provisions of this Agreement shall apply in
respect of all jurisdictions wherever situated; provided, however, that to the extent a Local Separation 

  
 6 

 
Agreement or an appendix attached hereto addresses employment, compensation and employee benefit matters, the terms of such Local Separation Agreement or such appendix shall govern in respect of
matters relating to employees employed in the applicable jurisdiction. 
 2.2 Employee Liabilities. On the applicable
Employee Transfer Date, the Company or another member of the Company Group shall assume and thereafter shall pay, perform, fulfill, and discharge, except as expressly provided in this Agreement, (i) all employment or service-related Liabilities
with respect to all Company Transferred Employees (and their dependents and beneficiaries) accrued and arising on and after the applicable Employee Transfer Date, and (ii) any Liabilities expressly transferred to the Company or a Company Group
member under this Agreement. 
 2.3 Plan Liabilities. Except as expressly set forth herein, Pfizer and the Company intend
that Pfizer and/or the applicable Pfizer Plan shall retain and be responsible for any Liabilities incurred by Company Transferred Employees under all Pfizer Plans prior to the applicable Plan Transition Date, or such earlier date specified herein in
respect of certain Plans. An appropriate allocation of the Company costs incurred prior to the Plan Transition Date shall be charged back to the Company. 
 ARTICLE III 
 GENERAL PLAN MATTERS 

3.1 Pfizer Plans. 
 (a) Employee Participation. Except as otherwise set forth herein, effective as of the applicable Plan Transition Date, all Company Transferred Employees shall cease participating in any Pfizer
Plans and shall cease accruing benefits in respect of such plans. 
 (b) Company Participation in Pfizer Plans. Except as
otherwise set forth herein, or except as otherwise agreed upon by the Parties, until the applicable Plan Transition Date, the Company shall continue to be a Participating Company in the Pfizer Health and Welfare Plans, the Pfizer Savings Plan, the
Pfizer Fringe Benefits, the Pfizer Life Insurance Plan, the Pfizer Long-Term Disability Plan and such other Pfizer Plans in which the Company Transferred Employees participate, subject to the terms and conditions provided herein and in said Plans.

 (c) Pfizer’s General Obligations as Plan Sponsor. Pfizer shall continue to administer, or cause to be
administered, the Pfizer Plans, and shall have the sole and absolute discretion and authority to interpret the Pfizer Plans, as set forth therein, subject to the specific arrangements provided in this Agreement. Pfizer shall administer all claims
incurred under the Pfizer Plans before the Plan Transition Date. Any determination made or settlements entered into by Pfizer with respect to such claims shall be final and binding. 

(d) Company’s General Obligations as Participating Company. With respect to any Pfizer Plan that provides benefits to a
Company Transferred Employee, the Company will cooperate with Pfizer on a timely basis with respect to such Plans, and the Company shall comply with the terms as set forth in such Plans or any procedures adopted pursuant thereto,

  
 7 

 
including (without limitation): (i) assisting in the administration of claims, to the extent requested by the claims administrator of said Pfizer Plan; (ii) cooperating fully with
Pfizer Plan auditors; (iii) the provision of payroll processing support; (iv) the qualification and administration of QDROs; (v) preserving the confidentiality of all financial arrangements Pfizer has or may have with any entity or
individual with whom Pfizer has entered into an agreement relating to said Pfizer Plan; and (vi) preserving the confidentiality of participant information to the extent not specified otherwise in this Agreement. In addition, the Company shall
provide, or cause to be provided, all participant information that is necessary or appropriate for the efficient and accurate administration of each Pfizer Plan or program that provides or has provided benefits to a Company Transferred Employee
during the respective period applicable to such Plan. Pfizer and its respective authorized agents shall, subject to applicable laws of confidentiality and data protection, be given reasonable and timely access to, and may make copies of, all
information relating to the subjects of this Agreement in the custody of the other party or its agents, to the extent necessary or appropriate for the administration of said Plans or programs. 

(e) Reporting and Disclosing Communications to Participants. While the Company is a Participating Company in the Pfizer Plans,
Pfizer shall take, or cause to be taken, all actions necessary or appropriate to facilitate the distribution of all Pfizer Plan-related communications and materials to participating the Company Employees and their beneficiaries, including (without
limitation) notices and enrollment material for the Pfizer Plans. To the extent that Pfizer fails to take such action which results in the failure of a distribution of required disclosure materials in connection with a Pfizer Plan which results in
any Liability to the Company, Pfizer shall indemnify the Company for such Liability. The Company shall provide all information needed by Pfizer to facilitate such Pfizer Plan-related communications. The Company shall take, or cause to be taken, all
actions necessary or appropriate to facilitate the distribution of all Pfizer Plan-related communications and materials to participating Company Transferred Employees and their beneficiaries. To the extent that the Company fails to take such action
which results in the failure of a distribution of required disclosure materials in connection with a Pfizer Plan which results in any Liability to Pfizer, the Company shall indemnify Pfizer for such Liability. 

(f) Pfizer Under No Obligation to Maintain Plans. Nothing in this Agreement shall preclude Pfizer, at any time, from amending,
merging, modifying, terminating, eliminating, reducing, or otherwise altering in any respect any Pfizer Plan, any benefit under any Pfizer Plan or any trust, insurance policy or funding vehicle related to any Pfizer Plan. To the extent that any such
amendment, modification, termination or elimination of a Pfizer Plan results in any Liability to the Company, Pfizer shall indemnify the Company for such Liability. 
 3.2 Company Plans. 
 (a) Establishment of Company Plans. Except as
otherwise set forth herein, or except as otherwise agreed upon by the Parties, effective as of the applicable Plan Transition Date, the Parties shall cause the Company to cease being a Participating Company in the Pfizer Plans and the Company, or
another member of the Company Group, shall adopt the Company Health and Welfare Plans, the Company Savings Plan, the Company Fringe Benefits, the Company Life Insurance Plan, the Company Long-Term Disability Plan, the Company Short-Term Disability
Plan, the Company Nonqualified Plans and such other Company Plans as may 

  
 8 

 
be determined to be appropriate by the Parties, which Plans shall generally correspond to the Pfizer Plans in which the Company Employees participated immediately prior to the Plan Transition
Date; provided, however, that the Company shall not be required to adopt any defined benefit pension plan, retirement medical plan or nonqualified plans except to the extent required by Law or any collective bargaining agreement. 

(b) Cooperation in Establishment of Company Plans. Prior to the applicable Plan Transition Date, Pfizer and the Company shall
cooperate to establish the Company Plans and the related insurance contracts, third party service provider agreements and other related agreements and arrangements. 
 (c) Company Under No Obligation to Maintain Plans. Nothing in this Agreement shall preclude the Company, at any time after the applicable Plan Transition Date, from amending, merging, modifying,
terminating, eliminating, reducing, or otherwise altering in any respect any Company Plan, any benefit under any Company Plan or any trust, insurance policy or funding vehicle related to any Company Plan. To the extent that any such amendment,
modification, termination or elimination of a Company Plan results in any Liability to any member of the Pfizer Group, the Company shall indemnify such Pfizer Group member for such Liability. 

(d) Transfers of Plan Assets. Except as otherwise specified in this Agreement, nothing in this Agreement shall require Pfizer to
transfer any Assets of any member of the Pfizer Group or any Pfizer Plan. 
 3.3 Terms of Participation by Company
Transferred Employees in Company Plans. 
 (a) Non-Duplication of Benefits. The Company Plans shall be, with respect
to Company Transferred Employees, in all respects the successors in interest to, and shall not provide benefits that duplicate benefits provided by, the corresponding Pfizer Plans. Pfizer and the Company shall agree on methods and procedures,
including amending the respective Plan documents, to prevent Company Transferred Employees from receiving duplicate benefits from the Pfizer Plans and the Company Plans. 
 (b) Service Credit. The Company shall credit service under the Company Plans accrued by Company Transferred Employees with, or otherwise recognized for purposes of benefit plans, programs, policies
or arrangements by Pfizer as of the applicable Plan Transition Date for all purposes (other than for benefit accrual purposes under any defined benefit pension plan of the Company). The service crediting provisions shall be subject to any
respectively applicable “service bridging,” “break in service,” “employment date,” or “eligibility date” rules under the Company Plans and the corresponding Pfizer Plans. 

  
 9 

 ARTICLE IV 
 EMPLOYMENT MATTERS FOR COMPANY TRANSFERRED EMPLOYEES 
 4.1 Liabilities
Related to Transfers of Employment. 
 (a) No Acceleration of Entitlements; No Severance. No provision of this
Agreement, the Separation Agreement, or any Ancillary Agreement shall be construed to create any right, or accelerate entitlement, to any compensation or benefit whatsoever on the part of any Company Employee, Company Transferred Employee or other
future, present or former employee of Pfizer or the Company under any Pfizer Plan or Company Plan, applicable Law or otherwise. 

(b) Assumption of Liability. Pfizer shall retain and be solely responsible for the administration of severance, indemnity or other
termination pay or other similar benefits in accordance with the terms and conditions of the applicable Pfizer severance plan or policy in effect as of the date of the applicable termination of employment (i) relating to or resulting from the
Company Group’s failure to offer employment to any Company Employee as of the applicable Employee Transfer Date (or failure to continue the employment of any Company Employee prior to the Plan Transition Date) or failure to offer or continue
employment on terms and conditions which would preclude any claims of constructive dismissal or similar claims under any applicable Law or other failure to comply with the terms of this Agreement prior to the Plan Transition Date or (ii) where
such severance, indemnity or termination pay or other benefits are required to be paid under applicable Law or a Pfizer Plan upon the Employee Transfer Date without regard to such terms and conditions or such continuation of employment. 

4.2 Assumption of Employment Agreements; Certain Other Terms of Employment. As of the applicable Employee Transfer Date, the
Company or another member of the Company Group shall have used reasonable efforts to assume all employment agreements, individual supplemental benefit agreements and other individual agreements entered into between a Company Transferred Employee and
a member of the Pfizer Group, and the Company shall indemnify and hold harmless Pfizer and each member of the Pfizer Group against any Liabilities pursuant to any such agreement. Each Company Transferred Employee shall be required at the request of
the Company to execute a new agreement regarding confidential information and proprietary developments in a form approved by the Company. In addition, nothing in the Separation Agreement, this Agreement or any Ancillary Agreement should be construed
to change the at-will status of any of the employees of the Pfizer Group or the Company Group. 
 4.3 Consultation with
Unions; Collective Bargaining Agreements. The Parties shall cooperate to inform and consult with any union representatives to the extent required by Law or an applicable collective bargaining, works council or similar agreement or arrangement
with any labor union or works council or which covers the Company Transferred Employees as of the Employee Transfer Date. As of the Employee Transfer Date, the Company, or another member of the Company Group, shall have assumed any collective
bargaining agreements in effect with respect to any Company Transferred Employee, and the Company shall indemnify and hold harmless Pfizer and each member of the Pfizer Group against any Liabilities pursuant to any such agreement. 

4.4 Employees with Work Visas or Permits; License to Do Business. Notwithstanding anything to the contrary in Section 4.1,
Company Employees who, on the Employee Transfer Date, are employed pursuant to a work or training visa or permit which authorizes employment only by a member of the Pfizer Group shall, to the extent required by applicable Law, remain employed by
such member of the Pfizer Group (providing services to the 

  
 10 

 
Company by secondment agreement to be entered into between the Parties) until the visa or permit is amended or a new visa or permit is granted to authorize employment by a member of the Company
Group. At the time such amended or new visa is issued, such Company Employees shall become Company Transferred Employees. 
 4.5
Warn Act and Other Notices. The Company shall provide any required notice under the Worker Adjustment and Retraining Notification Act (“WARN”) and any similar foreign, state, local or other applicable Law and otherwise to comply
with any such requirement with respect to any “plant closing” or “mass layoff” (as defined in WARN) or similar event occurring on or after the Employee Transfer Date and affecting Company Employees. The Company shall indemnify
and hold harmless the members of the Pfizer Group against any such Liabilities relating to WARN and any similar state or other applicable Law with respect to any events occurring on or after the Employee Transfer Date. 

ARTICLE V 

DEFINED BENEFIT PLANS 
 5.1 United States Defined Benefit Plans. 
 (a) No Assumption of Defined
Benefit Plan Liabilities. No member of the Company Group shall assume any Liability with respect to the Pfizer Retirement Plan or the Legacy Defined Benefit Plan. Following December 31, 2012, no Company Employee shall accrue any additional
benefits under the Pfizer Retirement Plan or the Legacy Defined Benefit Plan, except as contemplated under Subsection 5.1(b). 

(b) Separation from Service; Vesting; Grow-in. Pfizer or another member of the Pfizer Group shall amend the Pfizer Retirement Plan
and the Legacy Defined Benefit Plan to provide that, (i) Company Transferred Employees shall be 100% vested in their accrued benefits under the Pfizer Retirement Plan and the Legacy Defined Benefit Plan as of December 31, 2012; and
(ii) until the date that is earlier to occur of (A) the Company Transferred Employee’s termination of employment, (B) December 31, 2017, and (C) the commencement of benefits under the Pfizer Retirement Plan and the
Legacy Defined Benefit Plan, as applicable, Company Transferred Employees shall be given credit for service with members of the Company Group for purposes of eligibility for early retirement, early retirement subsidies and “Rule of 90”
benefits under the Pfizer Retirement Plan and the Legacy Defined Benefit Plan (but not for purposes of accruing additional benefits under the Pfizer Retirement Plan or the Legacy Defined Benefit Plan following December 31, 2012). 

(c) No Company Group member shall assume any Liability allocable to the Company Transferred Employees under the Pfizer Retirement Plan or
the Legacy Defined Benefit Plan; provided, however, that, to the extent that (i) any act or omission of the Company directly results in the inability of Pfizer to administer the Pfizer Retirement Plan or the Legacy Defined Benefit Plan in
compliance with the respective plan terms with respect to any Company Transferred Employee who participated under the Pfizer Retirement Plan or the Legacy Defined Benefit Plan and (ii) any related Liability is imposed on any member of the
Pfizer Group, the Company shall indemnify such Pfizer Group member for such Liability. To the extent that (i)

  
 11 

 
any act or omission of Pfizer directly results in the inability of Pfizer to administer the Pfizer Retirement Plan or the Legacy Defined Benefit Plan in compliance with the respective plan terms
with respect to any Company Transferred Employee who participated under the Pfizer Retirement Plan or the Legacy Defined Benefit Plan and (ii) any related Liability is imposed on any member of the Company Group, Pfizer shall indemnify such
Company Group member for such Liability. 
 ARTICLE VI 
 DEFINED CONTRIBUTION PLANS 
 6.1 United States Defined Contribution
Plan. 
 (a) Pfizer Savings Plan. Pfizer or another member of the Pfizer Group shall amend the Pfizer Savings Plan to
provide that: (i) Company Transferred Employees shall be 100% vested in their account balances under the Pfizer Savings Plan as of the Plan Transition Date; and (ii) effective December 31, 2012, Company Transferred Employees shall not
be eligible for a Retirement Savings Contribution (as defined in the Pfizer Savings Plan) with respect to benefits earned for services rendered in 2013 and thereafter. 
 (b) Company Savings Plan. The Company shall establish a qualified defined contribution plan (the “Company Savings Plan”), effective as of the Plan Transition Date. The Company
shall be responsible for taking all necessary, reasonable and appropriate action to establish, maintain and administer the Company Savings Plan so that it is qualified under Section 401(a) of the Code and that the related trust thereunder is
exempt under Section 501(a) of the Code, and as soon as reasonably practicable following the Plan Transition Date, the Company shall take all steps reasonably necessary to obtain a favorable determination from the IRS or obtain an opinion as to
such qualification. Immediately prior to the Plan Transition Date, the Company Transferred Employees shall cease to participate in the Pfizer Savings Plan and in the Legacy Savings Plan, and upon the Plan Transition Date, the Company Transferred
Employees shall be eligible to commence participation in the Company Savings Plan. Any minimum age or service requirements contained in the Company Savings Plan with respect to eligibility to participate generally or eligibility to share in any
employer contributions under such plan shall be waived or deemed satisfied for Company Transferred Employees to the extent waived or satisfied under the Pfizer Savings Plan and Legacy Savings Plan immediately prior to the Plan Transition Date.

 (c) Transfer of Pfizer Savings Plan Assets. Not later than thirty (30) days following the Plan Transition Date
(or such later time as mutually agreed by the Parties), Pfizer shall cause the accounts (including any outstanding participant loan balances) in the Pfizer Savings Plan and the Legacy Savings Plan attributable, in each case, to Company Transferred
Employees as of the Plan Transition Date and all of the Assets in the Pfizer Savings Plan and the Legacy Savings Plan related thereto to be transferred in-kind to the Company Savings Plan, and the Company shall cause the Company Savings Plan to
accept such transfer of accounts and underlying Assets and, effective as of the date of such transfer, to assume and to fully perform, pay and discharge, all obligations of the Pfizer Savings Plan and the Legacy Savings Plan relating to the accounts
of Company Transferred Employees (to the extent the Assets related to 

  
 12 

 
those accounts are actually transferred from the Pfizer Savings Plan and the Legacy Savings Plan to the Company Savings Plan). The transfer of Assets shall be conducted in accordance with
Section 414(l) of the Code, Treasury Regulation Section 1.414(1)-1 and Section 208 of ERISA. During the period after the Plan Transition Date and before such transfer of Assets, with respect to any Company Transferred Employee who has
an outstanding participant loan balance under the Pfizer Savings Plan or the Legacy Savings Plan, the Company shall provide that such amounts as are required to make payments on such loan in accordance with its terms are timely remitted as directed
by the administrator of the Pfizer Savings Plan or the Legacy Savings Plan for crediting under the Pfizer Savings Plan or the Legacy Savings Plan in respect of such loan, and Pfizer shall cause such administrator to apply such amounts in
satisfaction of such loan. 
 (d) Form 5310-A. No later than thirty (30) days prior to the Plan Transition Date,
Pfizer and the Company shall, to the extent necessary, file IRS Form 5310-A regarding the transfer of Assets and Liabilities from the Pfizer Savings Plan and the Legacy Savings Plan to the Company Savings Plan as provided in this Article 6.

 (e) Employer Securities. Pfizer and the Company each presently intend to preserve the right, for a period of time, of
Company Transferred Employees and Pfizer Employees to receive distributions in kind from, respectively, the Company Savings Plan and the Pfizer Savings Plan and the Legacy Savings Plan, if, and to the extent, investments under such plans are
comprised of Company common stock or Pfizer common stock. Each of the Company and Pfizer shall determine the extent to which and when Pfizer common stock (in the case of the Company Savings Plan) and Company common stock (in the case of the Pfizer
Savings Plan and the Legacy Savings Plan) shall cease to be investment alternatives thereunder. 
 ARTICLE VII 

NON-QUALIFIED PLANS 
 7.1 Pfizer Nonqualified Plans. 
 (a) In General. Except as set forth
in Section 7.1(b), no member of the Company Group shall assume any Liability with respect to any Pfizer Nonqualified Plan. The treatment of benefits under any Nonqualified Plan shall comply with Section 409A of the Code, to the extent
subject thereto, and shall be paid in accordance with such plan. 
 (b) Nonfunded Deferred Compensation and Supplemental
Savings Plan and Wyeth Supplemental Employee Savings Plan. 
 (i) Pfizer or another member of the Pfizer
Group shall amend the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and the Wyeth Supplemental Employee Savings Plan to provide that: (i) Company Transferred Employees shall be 100% vested in their account balances under
the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and the Wyeth Supplemental Employee Savings Plan as of the Plan Transition Date; and (ii) effective December 31, 2012, Company Transferred Employees shall not be
eligible for a Retirement Savings Contribution (as defined in the Pfizer Savings Plan) with respect to benefits earned for services rendered in 2013 and thereafter. 

  
 13 

 (ii) Effective as of the Plan Transition Date, the Company shall adopt a
supplemental savings plan to benefit eligible Company Transferred Employees who were participants in, or were eligible to accrue benefits under, the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and the Wyeth Supplemental
Employee Savings Plan, the terms of which shall generally correspond to the benefits provided under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and the Wyeth Supplemental Employee Savings Plan (the “Company
Supplemental Savings Plan”). Effective as of the Plan Transition Date, the Company shall assume all Liabilities allocable to the Company Transferred Employees under the Pfizer Nonqualified Deferred Compensation and Supplemental Savings Plan
and the Wyeth Supplemental Employee Savings Plan. 
 (iii) Effective as of the Plan Transition Date, to the
extent permitted by applicable Law, the Company shall cause the Company Supplemental Savings Plan to recognize and maintain all elections (including deferral, distribution and investment elections) and beneficiary designations with respect to the
Company Transferred Employees who participated under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and the Wyeth Supplemental Employee Savings Plan, to the extent such elections or designations are available under the
Company Supplemental Savings Plan, until a new election that by its terms supersedes such original election is made by the Company Transferred Employee in accordance with applicable Law and the terms and conditions of the Company Supplemental
Savings Plan. 
 (c) Deferred Compensation Plan and Wyeth Deferred Compensation Plan. 

(i) Effective as of the Plan Transition Date, the Company shall adopt a deferred compensation plan to benefit eligible
Company Transferred Employees , the terms of which shall generally correspond to the benefits provided under the Pfizer Deferred Compensation Plan and the Wyeth Deferred Compensation Plan (the “Company Deferred Compensation Plan”).
To the extent permitted or required by applicable Law, the Company shall cause the Company Deferred Compensation Plan to recognize and maintain all elections (including deferral, distribution and investment elections) and beneficiary designations
with respect to the Company Transferred Employees who participated under the Pfizer Deferred Compensation Plan and the Wyeth Deferred Compensation Plan, to the extent such elections or designations are available under the Company Deferred
Compensation Plan, until a new election that by its terms supersedes such original election is made by the Company Transferred Employee in accordance with applicable Law and the terms and conditions of the Company Deferred Compensation Plan.

 (ii) No Company Group member shall assume any Liability allocable to the Company Transferred Employees under
the Pfizer Deferred Compensation Plan or the Wyeth Deferred Compensation Plan; provided, however, that, to the extent that (i) any act or omission of the Company directly results in the inability of Pfizer to administer the

  
 14 

 
Pfizer Deferred Compensation Plan or the Wyeth Deferred Compensation Plan in compliance with Section 409A of the Code or any other Law or regulation and the terms of the respective Plan with
respect to any Company Transferred Employee who participated under the Pfizer Deferred Compensation Plan or the Wyeth Deferred Compensation Plan and (ii) any related Liability is imposed on any member of the Pfizer Group, the Company shall
indemnify such Pfizer Group member for such Liability. To the extent that (i) any act or omission of Pfizer directly results in the inability of Pfizer to administer the Pfizer Deferred Compensation Plan or the Wyeth Deferred Compensation Plan
in compliance with Section 409A of the Code or any other Law or regulation and the terms of the respective Plan with respect to any Company Transferred Employee who participated under the Pfizer Deferred Compensation Plan or the Wyeth Deferred
Compensation Plan and (ii) any related Liability is imposed on any member of the Company Group, Pfizer shall indemnify such Company Group member for such Liability. 
 (d) Nonfunded Supplemental Retirement Plan and Legacy SERPs. 

(i) Except as set forth in this Section 7.1(d), no Company Employee shall accrue any additional benefits under the
Pfizer Nonfunded Supplemental Retirement Plan or any Legacy SERPs following December 31, 2012. Pfizer or another member of the Pfizer Group shall amend the Nonfunded Supplemental Retirement Plan and the Legacy SERPs to provide that,
(i) Company Transferred Employees shall be 100% vested in their accrued benefits under such Plans as of December 31, 2012; and (iii) until the date that is earlier to occur of (A) the Company Transferred Employee’s
termination of employment, (B) December 31, 2017, and (C) the commencement of benefits under the Pfizer Retirement Plan, or a Legacy Retirement Plan, as the case may be. Company Transferred Employees shall be given credit for service
with members of the Company Group for purposes of vesting and eligibility for early retirement, early retirement subsidies and “Rule of 90” benefits under such Plans (but not for purposes of accruing additional benefits following
December 31, 2012). 
 (ii) No Company Group member shall assume any Liability allocable to the Company
Transferred Employees under the Pfizer Nonfunded Supplemental Retirement Plan or any Legacy SERPs; provided, however, that, to the extent that (i) any act or omission of the Company directly results in the inability of Pfizer to administer the
Pfizer Nonfunded Supplemental Retirement Plan or Legacy SERPs in compliance with Section 409A of the Code or any other Law or regulation and the terms of the respective Plan with respect to any Company Transferred Employee who participated
under the Pfizer Nonfunded Supplemental Retirement Plan or any Legacy SERPs and (ii) any related Liability is imposed on any member of the Pfizer Group, the Company shall indemnify such Pfizer Group member for such Liability. To the extent that
(i) any act or omission of Pfizer directly results in the inability of Pfizer to administer the Pfizer Nonfunded Supplemental Retirement Plan or Legacy SERPs in compliance with Section 409A of the Code or any other Law or regulation and
the terms of the respective Plan with respect to any Company Transferred Employee who participated under the Pfizer Nonfunded Supplemental Retirement Plan or any Legacy SERPs and (ii) any related Liability is imposed on any member of the
Company Group, Pfizer shall indemnify such Company Group member for such Liability. 

  
 15 

 ARTICLE VIII 
 HEALTH AND WELFARE PLANS 
 8.1 Allocation of Life Insurance
Liabilities. Each Pfizer Life Insurance Plan shall retain all Liabilities with respect to covered life insurance claims incurred prior to the Plan Transition Date by Company Transferred Employees and their dependents. The applicable Company Life
Insurance Plan shall be responsible for all Liabilities with respect to life insurance claims incurred after the Plan Transition Date by Company Transferred Employees and their dependents, it being understood that the provisions of this
Section 8.1 shall not require any member of the Company Group to maintain a plan providing life insurance benefits. For these purposes, a claim shall be deemed to have occurred on the date of the death of the insured person. 

8.2 Health and Welfare Plan Liabilities. The Pfizer Health and Welfare Plans (but not including the Pfizer Flexible Benefits
Plans) shall retain all Liabilities with respect to covered claims incurred prior to the Plan Transition Date by Company Transferred Employees and their dependents. The Company Health and Welfare Plans shall assume all Liabilities with respect to
covered claims incurred on or after the Plan Transition Date by all Company Transferred Employees and their dependents. For these purposes, a claim shall be deemed to have occurred at the time professional services, equipment or prescription drugs
covered by the applicable plan are obtained by the insured person. 
 8.3 Post-Separation Transitional Arrangements.

 (a) Coverage and Contribution Elections. As of the Plan Transition Date, the Company shall cause the Company Health and
Welfare Plans (including the Company Flexible Benefits Plans) to recognize and maintain all coverage and contribution elections made by Company Transferred Employees under the corresponding Pfizer Health and Welfare Plans (including the Pfizer
Flexible Benefits Plans) and apply such elections under the Company Health and Welfare Plans for the remainder of the period or periods for which such elections are by their terms applicable. All waiting periods and pre-existing condition exclusions
and actively-at-work requirements shall be waived with respect to the Company Transferred Employees who were not subject to any such waiting periods, exclusions or requirements under a Pfizer Health and Welfare Plan in which such employees
participate immediately prior to the Plan Transition Date. For the avoidance of doubt, nothing herein shall prevent the Company from conducting open enrollment and accepting elections under Company Health and Welfare Plans. 

(b) Deductibles and Out-of-Pocket Maximums. On and after the Plan Transition Date, the Company shall use commercially reasonable
efforts to cause the Company Health Plans to recognize and give credit for or take into account all amounts applied to deductibles, out-of-pocket maximums and co-payments with respect to which such expenses have been incurred by Company Transferred
Employees under the Pfizer Health Plans for the remainder of the calendar year in which the Plan Transition Date occurs. 
 8.4
Flexible Benefits Plans Spin-Off. The Parties shall take all steps necessary or appropriate so that the account balances (whether positive or negative) (the “Transferred Account Balances”) under the Pfizer Flexible Benefits
Plans of each Company Transferred 

  
 16 

 
Employee who has elected to participate therein in the year in which the Plan Transition Date occurs shall be transferred, as soon as practicable after the Plan Transition Date, from the Pfizer
Flexible Benefits Plans to the corresponding Company Flexible Benefits Plans. The Company Flexible Benefits Plans shall assume responsibility as of the Plan Transition Date for all outstanding dependent care and medical care claims under the Pfizer
Flexible Benefits Plans of each Company Transferred Employee for the year in which the Plan Transition Date occurs and shall assume and agree to perform the obligations of the analogous Pfizer Flexible Benefits Plans from and after the Plan
Transition Date. As soon as practicable after the Plan Transition Date, and in any event within 30 days after the amount of the Transferred Account Balances is determined or such later date as mutually agreed upon by the Parties, the Company shall
pay Pfizer the net aggregate amount of the Transferred Account Balances, if such amount is positive, and Pfizer shall pay the Company the net aggregate amount of the Transferred Account Balances, if such amount is negative. 

8.5 COBRA. The Pfizer Group shall be responsible for compliance with the health care continuation coverage requirements of COBRA
and the Pfizer Health and Welfare Plans with respect to Former Company Employees and qualified beneficiaries (as such term is defined under COBRA) who become eligible and elect to receive continuation health care coverage prior to the Plan
Transition Date. The Company or another member of the Company Group shall provide Pfizer with all necessary employee change notices and related information for covered dependents, spouses, qualified beneficiaries, and alternate recipients pursuant
to QMCSO, in accordance with applicable Pfizer COBRA policies and procedures. Effective as of the Plan Transition Date, the Company Group shall be solely responsible for compliance with the health care continuation coverage requirements of COBRA and
the Company Health and Welfare Plans for Company Employees and their qualified beneficiaries who become eligible or elect to receive continuation health care coverage on or following the Plan Transition Date. 

8.6 Disability Plans. Pfizer shall retain all Liabilities with respect to Company Transferred Employees who become eligible for
benefits under the Pfizer Long-Term Disability Plan after the Employee Transfer Date and before the Plan Transition Date. 
 8.7
Leave of Absence Programs and FMLA. Effective as of the Plan Transition Date, (i) the Company Group shall honor all terms and conditions of leaves of absence that have been granted by Pfizer to any Company Transferred Employee under a
Pfizer Leave of Absence Program or FMLA or other applicable Law regarding leave of absence before the Plan Transition Date, including such leaves that are to commence after the Plan Transition Date; (ii) the Company Group shall be solely
responsible for administering any such leave of absence and complying with FMLA and other applicable laws regarding leave of absence with respect to Company Transferred Employees; and (iii) the Company Group shall recognize all periods of
service of Company Transferred Employees with the members of the Pfizer Group, as applicable, to the extent such service is recognized by the members of the Pfizer Group for the purpose of eligibility for leave entitlement under the Pfizer Leave of
Absence Programs and FMLA and other applicable Laws; provided, however, that no duplication of benefits shall be required by the foregoing. 
  

  
 17 

 8.8 Pfizer Workers’ Compensation Program. 

(a) Assumption of Liabilities. The Company shall procure workers’ compensation insurance policies on behalf of the Company
Transferred Employees, to be effective as of the Plan Transition Date. The Company shall assume all Liabilities with respect to workers’ compensation claims made before, on or after the Plan Transition Date by all Company Transferred Employees.
For these purposes, a claim shall be deemed to have been made at the time the covered person applies for benefits. 
 (b)
Administration of Claims. 
 (i) Through the Plan Transition Date, the Pfizer Group shall continue to be
responsible for the administration of all workers’ compensation claims that are, or have been, made before the Plan Transition Date by Company Employees (“Company WC Claims”) and have been historically administered by Pfizer or
its third party administrator. The Company Group shall promptly reimburse the Pfizer Group for any and all direct and indirect costs and expenses related to any such administration. 

(ii) Effective as of the Plan Transition Date, the Company Group shall, to the extent legally permissible under the
applicable state’s workers’ compensation Laws, be responsible for the administration of all Company WC Claims, and if not legally permissible, the Pfizer Group shall be responsible for the administration of all Company WC Claims not
administered by the Company pursuant to this Subsection 8.8(b)(ii). Any determination made, or settlement entered into, by or on behalf of either party or its insurance company with respect to Company WC Claims for which it is administratively
responsible shall be final and binding upon the other party. The Company Group shall promptly reimburse the Pfizer Group for any and all direct and indirect costs and expenses related to any such settlement. 

ARTICLE IX 

RETIREE PROGRAMS 
 9.1 Retiree Programs. No member of the Company Group shall assume any Liability with respect to any Retiree Programs. Following December 31, 2012, no Company Employee shall accrue any
additional benefits under the Retiree Programs, except as contemplated in this Section 9.1. Pfizer shall provide or cause to be provided to each Company Transferred Employee (and his or her eligible dependents) who was eligible to retire on or
immediately prior to the Plan Transition Date and, upon such retirement, would have satisfied the eligibility requirements for retiree welfare coverage set forth in the applicable Retiree Program, with retiree welfare benefits and coverage following
such Company Transferred Employee’s retirement from the Company Group, with such benefits to be provided under the Retiree Program that was applicable to such Company Transferred Employee immediately prior to the Plan Transition Date, as such
applicable Retiree Program may be amended from time to time following the Effective Date as if such Company Transferred Employee had remained employed with Pfizer through the applicable retirement date. In addition, Pfizer or another member of the
Pfizer Group shall amend the Retiree Programs to provide that until the date that is earlier to occur of (A) the Company Transferred Employee’s termination of employment and (B) December 31, 2017, Company Transferred Employees
shall be given credit for service with 

  
 18 

 
members of the Company Group for purposes of eligibility for participation in the Retiree Programs, but not for purposes of the retiree medical subsidy under the Pfizer Retiree Medical Plan. The
provisions of this Section 9.1 shall not be construed to require any member of the Pfizer Group to maintain a Retiree Program or to prevent the amendment in any manner of any Retiree Program. The participation by any Company Transferred
Employee in a Retiree Program shall be subject to such right of amendment or termination. 
 ARTICLE X 

CASH BONUS PLANS 
 10.1 Annual Incentive Plans. Pfizer shall retain and perform all Liabilities with respect to the participation of each Company Transferred Employee who is participating in any cash-based annual
bonus or other annual incentive compensation plan of a Pfizer Group member with respect to performance periods that are ongoing as of December 31, 2012 and completed performance periods as of December 31, 2012. Effective as of
January 1, 2013, the Company shall establish an annual bonus or other cash-based annual incentive compensation plan for the benefit of eligible Company Transferred Employees and shall be responsible for the annual bonus payable to the Company
Transferred Employees in respect of the full 2013 calendar year. 
 ARTICLE XI 

EQUITY COMPENSATION 
 11.1 Pfizer Equity. 
 (a) Options. Each outstanding Option held by a
Company Transferred Employee that is unvested immediately prior to the Disposition Date shall vest on the Disposition Date. All vested Options shall be exercisable for Pfizer common stock (i) in accordance with the terms of the Pfizer Stock
Plan and the applicable award agreement in respect of retirement-eligible Option-holders (determined as of the Disposition Date) or (ii) in respect of Option-holders who are not eligible for retirement as of the Disposition Date, until the
earliest to occur of (A) the three year anniversary of the Disposition Date, (B) the Option-holder’s termination of employment from the Company, and (C) the expiration of the Option. Prior to the Disposition Date, Pfizer may take
such actions, including but not limited to, adjustment of Options and/or modifications of any applicable Option terms as it deems appropriate. 
 (b) Restricted Stock Units, TSRUs, PSAs. At the Disposition Date, each Restricted Stock Unit, TSRU and PSA held by Company Transferred Employees shall continue to be a right to receive Pfizer
common stock or the cash value thereof, subject to the terms and conditions (including the same vesting schedule and circumstances) set forth in the Pfizer Stock Plan and in the applicable award agreement. Prior to the Disposition Date, Pfizer may
take such actions, including but not limited to, adjustment of Restricted Stock Units, TSRUs or PSAs and/or modifications of any applicable terms of such awards as it deems appropriate. At the Disposition Date, Pfizer may determine to accelerate the
vesting and, in some cases the settlement, of certain of the awards, subject, in each case, to the requirements of Section 409A of the Code, the terms of the Pfizer Stock Plan and the applicable award agreements and any elections to defer.

  
 19 

 (c) No Company Group member shall assume any Liability allocable to the Company Transferred
Employees in connection with awards under the Pfizer Stock Plan; provided, however, that to the extent that (i) any act or omission of the Company directly results in the inability of Pfizer to administer such awards in compliance with
Section 409A of the Code or any other Law or regulation and the respective plan terms with respect to any Company Transferred Employee and (ii) any related Liability is imposed on any member of the Pfizer Group, the Company shall indemnify
such Pfizer Group member for such Liability. To the extent that (i) any act or omission of Pfizer directly results in the inability of Pfizer to administer such awards in compliance with Section 409A of the Code or any other Law or
regulation and the respective plan terms with respect to any Company Transferred Employee and (ii) any related Liability is imposed on any member of the Company Group, Pfizer shall indemnify such Company Group member for such Liability.

 11.2 Equity-Related Tax Matters. Pfizer shall be entitled to claim any compensation deduction associated with the
exercise by a holder of a Pfizer Option, or the vesting of a Pfizer Restricted Stock Unit, TSRU and PSA, as the case may be, on any duly filed US federal, state, local or foreign income tax return for the year of exercise or vesting, and neither the
Company nor any of its Affiliates shall take any inconsistent position in connection therewith. If, notwithstanding the foregoing, a Final Determination shall provide that the benefit of a tax deduction related to the payment of such
compensation shall not belong to Pfizer but to the Company, then with respect to any such compensation claimed during the taxable year or years covered by such Final Determination as well as any such compensation deduction claimed during subsequent
taxable years on any previously filed income tax return, the Company (i) shall be entitled to claim the benefit of the deduction on any applicable income tax return (including any amended income tax return) and (ii) shall, in any event,
pay to Pfizer within 30 days from the date of such Final Determination an amount equal to the incremental income tax payable by Pfizer as a result of the loss of such deduction, as well as any interest payable by Pfizer with respect to such
incremental income tax, each as determined by Pfizer in its reasonable judgment. To the extent that any Pfizer Option that is subject to this Agreement has not yet been exercised, or any Pfizer Restricted Stock Unit, TSRU or PSA that is subject
to this Agreement has not yet vested, in each case at the time such Final Determination occurs, then to the extent that such Final Determination would be inconsistent with Pfizer receiving the benefit of any tax deduction related to the payment of
such compensation upon such exercise or vesting, (i) Pfizer shall not claim the benefit of any associated deduction on its tax return for the year of exercise or vesting, (ii) the Company shall be entitled to claim the benefit of the
deduction on any applicable income tax return for the year of exercise or vesting and (iii) in any event, the Company shall pay to Pfizer within 30 days of the such exercise or vesting an amount equal to the product of (x) the tax
deduction resulting from such compensation and (y) the combined federal, state and local tax rates applicable to Pfizer for the year of such exercise or vesting, in each case as determined by Pfizer in its reasonable judgment. 

  
 20 

 ARTICLE XII 
 SEPARATION PAY; VACATION; UNEMPLOYMENT INSURANCE 
 12.1 Separation
Pay. Except as specified otherwise in this Agreement, the Company shall assume and be solely responsible for all Liabilities with respect to severance benefits attributable to the termination of employment after the Employee Transfer Date of
Company Transferred Employees, to the extent such individual is eligible for severance pursuant to the terms of the applicable Pfizer or Company severance pay plan or policy as in effect as of the date of the employee’s termination of
employment. 
 12.2 Paid Time Off Benefits. The Company or another member of the Company Group shall assume and honor all
paid time off accrued but not yet taken by Company Transferred Employees as of the Employee Transfer Date (including banked vacation). 
 12.3 Unemployment Insurance Program. No later than the Plan Transition Date, the Company shall use its commercially reasonable best efforts to procure an agreement with an unemployment insurance
vendor to provide unemployment insurance for Company Transferred Employees. 
 ARTICLE XIII 

OTHER EMPLOYMENT-RELATED MATTERS 
 13.1 Confidentiality and Proprietary Information. No provision of the Separation Agreement or any Ancillary Agreement shall be deemed to release any individual for any violation of the Pfizer
non-competition guidelines or any agreement or policy pertaining to confidential or proprietary information of any member of the Pfizer Group, or otherwise relieve any individual of his or her obligations under such non-competition guidelines,
agreement or policy. 
 ARTICLE XIV 
 CERTAIN PAYROLL AND TAX MATTERS 
 14.1 Payroll and Withholding.

 (a) Accrued Payroll. Pfizer shall retain all Liabilities related to payroll with respect to the Company Transferred
Employees, to the extent such Liabilities relate to service prior to the Plan Transition Date, and shall pay such amounts on or after the Plan Transition Date in accordance with its standard payroll practices. Effective as of the Plan Transition
Date, the Company Group shall establish its own payroll system for Company Transferred Employees. 
 (b) Income Reporting,
Withholding. Pfizer and the Company shall, to the extent practicable, (i) treat the Company (or a member of the Company Group designated by the Company) as a “successor employer” and Pfizer (or the appropriate Pfizer Group member)
as a “predecessor,” within the meaning of Sections 3121(a)(1) and 3306(b)(1) of the Code, with respect to Company Transferred Employees for purposes of taxes imposed under the United

  
 21 

 
States Federal Unemployment Tax Act or the United States Federal Insurance Contributions Act, and (ii) cooperate with each other to avoid, to the extent possible, the filing of the more than
one IRS Form W-2 with respect to each Company Transferred Employee for the year in which the Effective Date occurs. Without limiting in any manner the obligations and Liabilities of the parties under the Tax Matters Agreement, Pfizer, each Pfizer
Group member, the Company and each Company Group member shall each bear its responsibility for payroll tax obligations and for the proper reporting to the appropriate governmental authorities of compensation earned by their respective employees
after the Employee Transfer Date, including compensation related to the exercise of options or the vesting or exercise of other equity awards, subject to Section 11.2 hereof. 

(c) Delivery of, and Access to, Documents and Other Information. Concurrently with the Employee Transfer Date, Pfizer shall cause
to be delivered to the Company the employee information set forth on all withholding certificates executed by Company Transferred Employees as of the Employee Transfer Date. For such period as Pfizer and the Company may mutually agree in writing,
Pfizer shall make reasonably available to the Company all forms, documents or information, no matter in what format stored, relating to compensation or payments made to any Company Transferred Employee. Such information may include, but is not
limited to, information concerning employee payroll deductions, payroll adjustments, records of time worked, tax records (e.g., Forms W-2, 1099, W-4, 940 and 941 and applicable counterparts in other jurisdictions), and information concerning
garnishment of wages or other payments. 
 (d) Consistency of Tax Positions; Duplication. Pfizer and the Company shall
individually and collectively make commercially reasonable best efforts to avoid unnecessarily duplicated federal, state or local payroll taxes, insurance or workers’ compensation contributions, or unemployment contributions arising on or after
the Employee Transfer Date. Pfizer and the Company shall cooperate with a view toward taking consistent reporting and withholding positions with respect to any such taxes or contributions. 

14.2 Personnel and Pay Records. Notwithstanding anything to the contrary in the Separation Agreement, to the extent permitted by
applicable Law, the original of all records created prior to the Employee Transfer Date (or such later date of transfer of employment, as applicable) set forth in the personnel files of the Company Transferred Employees (including, but not limited
to, information regarding such employee’s ranking or promotions, the existence and nature of garnishment orders or other judicial or administrative actions or orders affecting the employee’s compensation, and performance evaluations) shall
be transferred to the applicable member of the Company Group as of the Employee Transfer Date (or such later date of transfer of employment, as applicable). The originals of all personnel records of all Former Company Employees shall remain with the
applicable member of the Pfizer Group; provided that Pfizer shall permit the Company or its Affiliates or successors or their authorized representatives to have full access to all such personnel records to the extent reasonably necessary in order
for the members of the Company Group or its successors to respond to a subpoena, court order, audit, investigation or otherwise as required by applicable Law or in connection with any pending or threatened lawsuits, actions, arbitrations, claims,
complaints, investigations or other proceedings. The Company or its Affiliates (or their respective successors) shall retain the personnel records for a period of at least ten (10) years following the IPO. The members of the Company Group

  
 22 

 
shall permit Pfizer and its authorized representatives to have full access upon reasonable notice during normal business hours to all the personnel records during the ten (10) year retention
period in order for the members of the Pfizer Group to respond to a subpoena, court order, audit or investigation, to obtain data for pension or other benefits, or otherwise as required by applicable Law, and the members of the Company Group shall
provide Pfizer, upon the reasonable request of Pfizer and at the expense of Pfizer, with copies of such personnel records. 

ARTICLE XV 

ADMINISTRATIVE PROVISIONS 
 15.1 Sharing of Participant Information. In addition to the responsibilities and obligations of Pfizer and the Company specified in the Separation Agreement and the schedules thereto, Pfizer and
the Company shall share, or cause to be shared, all participant information that is necessary or appropriate for the efficient and accurate administration of each of the Pfizer Plans and the Company Plans during the respective periods applicable to
such Plans as the Company and Pfizer may mutually agree, subject to applicable Laws (including those with respect to privacy, confidentiality and data protection). Subject to such Laws, Pfizer and the Company and their respective authorized agents
shall be given reasonable and timely access to, and may make copies of, all information relating to the subjects of this Agreement in the custody of the other party or its agents, to the extent necessary or appropriate for such administration.

 15.2 Audits Regarding Vendor Contracts. From the period beginning on the Plan Transition Date and ending on such date
as Pfizer and the Company may mutually agree in writing, Pfizer and the Company and their duly authorized representatives shall have the right to conduct joint audits with respect to any vendor contracts that relate to both the Pfizer Health and
Welfare Plans and the Company Health and Welfare Plans. The scope of such audits shall encompass the review of all correspondence, account records, claim forms, canceled drafts (unless retained by the bank), provider bills, medical records submitted
with claims, billing corrections, vendor’s internal corrections of previous errors and any other documents or instruments relating to the services performed by the vendor under the applicable vendor contracts. Pfizer and the Company shall agree
on the performance standards, audit methodology, auditing policy and quality measures, reporting requirements, and the manner in which costs incurred in connection with such audits will be shared. 

15.3 Regulatory Matters. Pfizer and the Company shall make such filings and applications to regulatory agencies, including the IRS
and DOL, as may be necessary or appropriate in connection with the transactions contemplated by this Agreement. The Company and Pfizer shall cooperate fully with one another on any issue relating to the transactions contemplated by this Agreement
for which Pfizer and/or the Company elects to seek a determination letter or private letter ruling from the IRS, an advisory opinion from the DOL or other ruling from a local regulatory agency. 

15.4 Fiduciary Matters. Pfizer and the Company each acknowledge that actions contemplated to be taken pursuant to this Agreement
may be subject to fiduciary duties or standards of conduct under ERISA or other applicable Law, and no party shall be deemed to be in violation of this Agreement if such party fails to comply with any provisions hereof based upon such party’s
good faith determination that to do so would violate such a fiduciary duty or standard. 

  
 23 

 15.5 Consent of Third Parties. If any provision of this Agreement is dependent on the
consent of any third party (such as a vendor) and such consent is withheld, Pfizer and the Company shall use their commercially reasonable best efforts to implement the applicable provision. If any provision of this Agreement cannot be implemented
due to the failure of such third party to consent, Pfizer and the Company shall negotiate in good faith to implement the provision in a mutually satisfactory manner. 
 ARTICLE XVI 
 GENERAL PROVISIONS 

16.1 Cooperation. 
 (a) Duties of Company. Following the Effective Date, the Company shall cooperate, and shall cause the members of the Company Group to cooperate, fully with the members of the Pfizer Group in the
prosecution, defense and settlement of any claims for which any member of the Pfizer Group retains Liability under this Agreement. Such cooperation shall include (i) affording the applicable member of the Pfizer Group, its counsel and its other
representatives reasonable access, upon reasonable written notice during normal business hours, to all relevant personnel, properties, books, contracts, commitments and records, (ii) furnishing promptly to the applicable member of the Pfizer
Group, its counsel and its other representatives such information as they reasonably requested, and (iii) providing any other assistance to the applicable member of the Pfizer Group, its counsel and its other representatives as they reasonably
request. Pfizer shall reimburse the Company for reasonable costs and expenses incurred in assisting Pfizer pursuant to this Subsection 16.1(a). 
 (b) Duties of Pfizer. Following the Effective Date, Pfizer shall cooperate, and shall cause the members of the Pfizer Group to cooperate, fully with the members of the Company Group in the
prosecution, defense and settlement of any claims for which any member of the Company Group assumes Liability under this Agreement. Such cooperation shall include (i) affording the applicable member of the Company Group, its counsel and its
other representatives reasonable access, upon reasonable written notice during normal business hours, to all relevant personnel, properties, books, contracts, commitments and records, (ii) furnishing promptly to the applicable member of the
Company Group, its counsel and its other representatives such information as they reasonably request, and (iii) providing any other assistance to the applicable member of the Company Group, its counsel and its other representatives as they
reasonably request. The Company shall reimburse Pfizer for reasonable costs and expenses incurred in assisting the Company pursuant to this Subsection 16.1(b). 
 16.2 Relationship of Parties. Nothing in this Agreement shall be deemed or construed by the Parties or any third party as creating the relationship of principal and agent, partnership or joint
venture between the Parties, the understanding and agreement being that no provision contained herein, and no act of the Parties, shall be deemed to create any relationship between the Parties other than the relationship set forth herein.

  
 24 

 16.3 Affiliates. Each of Pfizer and the Company shall cause to be performed, and
hereby guarantee the performance of, any and all actions of the members of the Pfizer Group or the Company Group, respectively. 

16.4 No Third Party Remedies. The provisions of this Agreement are solely for the benefit of the Parties and are not intended to
confer upon any Person (including employees of the Parties hereto) except the Parties any rights or remedies hereunder, and there are no third party beneficiaries of this Agreement and this Agreement shall not provide any third person (including
employees of the Parties) with any remedy, claim, liability, reimbursement, claim of action or other right in excess of those existing without reference to this Agreement. 
 16.5 Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the Laws of the State of New York, without regard to the conflict of laws principles thereof
that would result in the application of any Law other than the Laws of the State of New York. 
 16.6 Severability. If
any provision of this Agreement or the application thereof to any Person or circumstance is determined by a court of competent jurisdiction to be invalid, void or unenforceable, the remaining provisions hereof or the application of such provision to
Persons or circumstances or in jurisdictions other than those as to which it has been held invalid or unenforceable, shall remain in full force and effect and shall in no way be affected, impaired or invalidated thereby, so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination, the Parties shall negotiate in good faith in an effort to agree upon such a suitable and equitable provision to
effect the original intent of the Parties. 
 16.7 Amendment and Termination. This Agreement may be amended or terminated
at any time prior to the Disposition Date by and in the sole discretion of Pfizer without the approval of the Company. This Agreement may be amended at any time on after the Disposition Date by mutual consent in writing of Pfizer and the Company.

 16.8 Conflict. Except as otherwise set forth in Section 2.1 herein, in the event of any conflict between the
provisions of this Agreement and the Separation Agreement, any Ancillary Agreement, or Plan, the provisions of this Agreement shall control. 
 16.9 Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts
have been signed by each of the Parties and delivered to the other Party. Execution of this Agreement or any other documents pursuant to this Agreement by facsimile or other electronic copy of a signature shall be deemed to be, and shall have the
same effect as, executed by an original signature. 

  
 25 

 IN WITNESS WHEREOF, each of the Parties have caused this Agreement to be executed on its
behalf by its officers thereunto duly authorized on the day and year first above written. 
  

			
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 26Form of Zoetis Inc. 2013 Equity and Incentive Plan

 Exhibt 10.16 
 FORM OF 
 ZOETIS INC. 

2013 EQUITY AND INCENTIVE PLAN 
 ARTICLE I 
 PURPOSE 

The purposes of the Zoetis Inc. 2013 Equity and Incentive Plan (as it may be amended, the “Plan”) are to provide long-term
incentives to those individuals with significant responsibility for the success and growth of the Company and its Affiliates, to align the interests of such individuals with those of the Company’s stockholders, to assist the Company in
recruiting, retaining and motivating qualified employees and to provide an effective means to link pay to performance for such employees. 
 ARTICLE II 
 DEFINITIONS AND CONSTRUCTION 

Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates
otherwise. The singular pronoun shall include the plural where the context so indicates. 
 2.1 “Administrator”
shall have the meaning provided in Section 12.1 hereof. 
 2.2 “Affiliate” shall mean (i) any Parent
or Subsidiary, (ii) any entity that, directly or through one or more intermediaries, is controlled by the Company, or (iii) any entity in which the Company has a significant equity interest, in each case as determined by the Committee.

 2.3 “Applicable Accounting Standards” shall mean Generally Accepted Accounting Principles in the United
States, International Financial Reporting Standards or such other accounting principles or standards as may apply to the Company’s financial statements under United States federal securities laws from time to time. 

2.4 “Award” shall mean an Option, a Restricted Stock award, a Restricted Stock Unit award, a Performance Award (which
includes, but is not limited to, cash bonuses as set forth in Article IX), a Dividend Equivalent award, a Stock Payment award, an award of Stock Appreciation Rights, or Other Incentive Award, which may be awarded or granted under the Plan.

 2.5 “Award Agreement” shall mean the written notice, agreement, contract or
other instrument or document evidencing an Award, including through an electronic medium, which shall contain such terms and conditions with respect to an Award as the Administrator shall determine, consistent with the Plan. 

2.6 “Beneficial Owner” (or any variant thereof) has the meaning defined in Rule 13d-3 under the Exchange Act.

 2.7 “Board” shall mean the Board of Directors of the Company. 

2.8 “Change in Capitalization” shall have the meaning provided in Section 3.2(a) hereof. 

2.9 “Change in Control” shall be deemed to have occurred if an event set forth in any one of the following paragraphs
shall have occurred: 
 (a) any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company
(not including the securities beneficially owned by such Person or any securities acquired directly from the Company or any Affiliate thereof) representing 20% or more of the combined voting power of the Company’s then outstanding securities,
excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (1) of paragraph (c) below; or 
 (b) the following individuals cease for any reason to constitute a majority of the number of directors then serving on the Board: individuals who, on the date hereof, constitute the Board and any new
director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of directors of the Company) whose
appointment or election by the Board or nomination for election by the Company’s stockholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date
hereof or whose appointment, election or nomination for election was previously so approved or recommended; or 
 (c) there is
consummated a merger, amalgamation or consolidation of the Company or any Subsidiary thereof with any other corporation, other than (1) a merger, amalgamation or consolidation which results in the voting securities of the Company outstanding
immediately prior to such merger, amalgamation or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 50% of the combined voting
power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger, amalgamation or consolidation or (2) a merger, amalgamation or consolidation effected to implement a
recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities Beneficially Owned by such Person any securities
acquired directly from the Company or its Affiliates) representing 50% or more of the combined voting power of the Company’s then outstanding securities; or 

  
 2 

 (d) the stockholders of the Company approve a plan of complete liquidation or dissolution
of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than (1) a sale or disposition by the Company of all or substantially all of the
Company’s assets to an entity, at least fifty percent (50%) of the combined voting power of the voting securities of which are owned by stockholders of the Company following the completion of such transaction in substantially the same
proportions as their ownership of the Company immediately prior to such sale or (2) a sale or disposition of all or substantially all of the Company’s assets immediately following which the individuals who comprise the Board immediately
prior thereto constitute at least a majority of the board of directors of the entity to which such assets are sold or disposed or, if such entity is a subsidiary, the ultimate parent thereof. 
 Notwithstanding the foregoing, a Change in Control shall not be deemed to have occurred by virtue of (i) the consummation of any transaction or series of integrated transactions immediately following
which the holders of Common Stock immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Company
immediately following such transaction or series of transactions, or (ii) the consummation of the Distribution (as such term is defined in that certain Global Separation Agreement entered into between Pfizer Inc. and the Company). 

For each Award that constitutes deferred compensation under Section 409A of the Code, a Change in Control shall be deemed to have occurred under the
Plan with respect to such Award, resulting in the payment of such Award, only if a change in the ownership or effective control of the Company or a change in ownership of a substantial portion of the assets of the Company shall also be deemed to
have occurred under Section 409A of the Code. 
 2.10 “Code” shall mean the Internal Revenue Code of 1986,
as amended. 
 2.11 “Committee” shall mean the Compensation Committee of the Board, or another committee or
subcommittee of the Board described in Article XII hereof. 
 2.12 “ Common Stock” shall mean the common stock
of the Company, par value $0.01 per share. 
 2.13 “Company” shall mean Zoetis Inc., a Delaware corporation,
and any successor corporation. 
 2.14 “Covered Employee” shall mean any Employee who is a “covered
employee” within the meaning of Section 162(m) of the Code. 
 2.15 “Director” or “Non-Employee
Director” shall mean a non-employee member of the Board, as constituted from time to time. 
 2.16
“Disaffiliation” means a Subsidiary’s or Affiliate’s ceasing to be a Subsidiary or Affiliate for any reason (including, without limitation, as a result of a public offering, or a spinoff or sale by the Company, of the
stock of the Subsidiary or Affiliate) or a sale of a division of the Company or its Affiliates. 

  
 3 

 2.17 “Dividend Equivalent” shall mean a right to receive the equivalent
value (in cash or Shares) of dividends paid on Shares, awarded under Section 9.2 hereof. 
 2.18 “Effective
Date” shall mean [                    ]. 
 2.19 “Eligible Individual” shall mean any natural person who is an Employee or a Non-Employee Director, as determined by the Administrator. 

2.20 “Employee” shall mean any officer or other employee (as determined in accordance with Section 3401(c) of the
Code) of the Company or any Affiliate. 
 2.21 “Exchange Act” shall mean the Securities Exchange Act of 1934,
as amended from time to time. 
 2.22 “Fair Market Value” shall mean, as of any given date, the value of a
Share determined as follows: 
 (a) if the Common Stock is (i) listed on any established securities exchange (such as the
New York Stock Exchange, the NASDAQ Global Market and the NASDAQ Global Select Market), (ii) listed on any national market system or (iii) listed, quoted or traded on any automated quotation system, its Fair Market Value shall be the
closing sales price for a Share as quoted on such exchange or system for such date or, if there is no closing sales price for a Share on the date in question, the closing sales price for a Share on the last preceding date for which such quotation
exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 
 (b) if the Common
Stock is traded only otherwise than on a securities exchange and is not quoted on the NASDAQ, the closing quoted selling price of the Common Stock on such date as quoted in “pink sheets” published by the National Daily Quotation Bureau;

 (c) if the Common Stock is not listed on an established securities exchange, national market system or automated quotation
system, but the Common Stock is regularly quoted by a recognized securities dealer, its Fair Market Value shall be the mean of the high bid and low asked prices for such date or, if there are no high bid and low asked prices for a Share on such
date, the high bid and low asked prices for a Share on the last preceding date for which such information exists, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or 

(d) if the Common Stock is neither listed on an established securities exchange, national market system or automated quotation system
nor regularly quoted by a recognized securities dealer, its Fair Market Value shall be established by the Committee in good faith on the date awarded. 
 2.23 “Greater Than 10% Stockholder” shall mean an individual then-owning (within the meaning of Section 424(d) of the Code) more than ten percent (10%) of the total combined
voting power of all classes of stock of the Company or any “parent corporation” or “subsidiary corporation” (as defined in Sections 424(e) and 424(f) of the Code, respectively). 

  
 4 

 2.24 “Incentive Stock Option” shall mean an Option that is intended to
qualify as an incentive stock option and conforms to the applicable provisions of Section 422 of the Code. 
 2.25
“Individual Award Limit” shall mean the cash and Share limits applicable to Awards granted under the Plan, as set forth in Section 3.3 hereof. 
 2.26 “Non-Qualified Stock Option” shall mean an Option that is not an Incentive Stock Option or which is designated as an Incentive Stock Option but does not meet the applicable
requirements of the Code. 
 2.27 “Option” shall mean a right to purchase Shares at a specified exercise price,
granted under Article VI hereof. An Option shall be either a Non-Qualified Stock Option or an Incentive Stock Option; provided, however, that Options granted to Non-Employee Directors shall only be Non-Qualified Stock Options. 

2.28 “Other Incentive Award” shall mean an Award denominated in, linked to or derived from Shares or value metrics
related to Shares, granted pursuant to Section 9.4 hereof. 
 2.29 “Parent” shall mean any entity (other
than the Company), whether domestic or foreign, in an unbroken chain of entities ending with the Company if each of the entities other than the Company beneficially owns, at the time of the determination, securities or interests representing more
than fifty percent (50%) of the total combined voting power of all classes of securities or interests in one of the other entities in such chain. 
 2.30 “Participant” shall mean an Eligible Individual who has been granted an Award. 
 2.31 “Performance Award” shall mean an Award that is granted under Section 9.1 hereof. 
 2.32 “Performance-Based Compensation” shall mean any compensation that is intended to qualify as “performance-based compensation” as described in Section 162(m)(4)(C) of
the Code. 
 2.33 “Performance Goals” shall mean the performance goals (and adjustments) established by the
Committee for a Performance Period, based on one or more of the following criteria: 
 (a)(i) net earnings (either before or
after one or more of the following: (A) interest, (B) taxes, (C) depreciation, (D) amortization and (E) non-cash equity-based compensation expense); (ii) gross or net sales or revenue; (iii) net income (either
before or after taxes); (iv) adjusted net income; (v) operating earnings or profit; (vi) cash flow (including, but not limited to, operating cash flow and free cash flow); (vii) return on assets; (viii) return on capital;
(ix) return on stockholders’ equity; (x) total stockholder return; (xi) return on sales; (xii) gross or net profit or operating margin; (xiii) costs; (xiv) funds from operations; (xv) expenses;
(xvi) working capital; (xvii) earnings per Share; (xviii) adjusted earnings per Share; (xix) price per Share; (xx) implementation or completion of critical projects; (xxi) market share; (xxii) debt

  
 5 

 
levels or reduction; (xxiii) customer retention; (xxiv) sales-related goals; (xxv) customer satisfaction and/or growth; (xxvi) research and development achievements;
(xxvii) financing and other capital raising transactions; (xxviii) capital expenditures, and (xxix) economic profit, any of which may be measured either in absolute terms for the Company or any operating unit of the Company or as
compared to any incremental increase or decrease or as compared to results of a peer group or to market performance indicators or indices. 
 (b) Performance Goals may be expressed in terms of overall Company performance, or the performance of an Affiliate or one or more divisions, business units or product lines. In addition, such Performance
Goals may be based upon the attainment of specified levels of performance under one or more of the measures described above relative to the performance of other corporations or the performance of an index, survey or other benchmark. 

(c) The Committee may, in its sole discretion, provide that one or more objectively determinable adjustments shall be made to one or
more of the Performance Goals. Such adjustments may include, but are not limited to, one or more of the following: (i) items related to a change in accounting principles; (ii) items relating to financing activities; (iii) expenses for
restructuring or productivity initiatives; (iv) other non-operating items; (v) items related to acquisitions; (vi) items attributable to the business operations of any entity acquired by the Company during the Performance Period;
(vii) items related to the disposal or sale of a business or segment of a business; (viii) items related to discontinued operations that do not qualify as a segment of a business under Applicable Accounting Standards; (ix) items
attributable to any stock dividend, stock split, combination or exchange of stock occurring during the Performance Period; (x) any other items of significant income or expense which are determined to be appropriate adjustments; (xi) items
relating to unusual or extraordinary corporate transactions, events or developments; (xii) items related to amortization of acquired intangible assets; (xiii) items that are outside the scope of the Company’s core, on-going business
activities; (xiv) items related to acquired in-process research and development; (xv) items relating to changes in tax laws; (xvi) items relating to major licensing or partnership arrangements; (xvii) items relating to asset
impairment charges; (xviii) items relating to gains or losses for litigation, arbitration and contractual settlements; or (xix) items relating to any other unusual or nonrecurring events or changes in applicable laws, accounting principles
or business conditions. 
 2.34 “Performance Period” shall mean one or more periods of time, which may be of
varying and overlapping durations, as the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance Award.
Notwithstanding the foregoing, in no event shall the Performance Period be less than one (1) year in duration. 
 2.35
“Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any Subsidiary thereof,
(ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary thereof, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a
corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of Shares of the Company. 

  
 6 

 2.36 “Plan” shall have the meaning set forth in Article I. 

2.37 “Restricted Stock” shall mean an Award of Shares made under Article VII hereof that is subject to certain
restrictions and may be subject to risk of forfeiture or repurchase. 
 2.38 “Restricted Stock Unit” shall mean
a contractual right awarded under Article VIII hereof to receive in cash or Shares the Fair Market Value of a Share of Common Stock. 
 2.39 “Restriction Period” shall mean the period of time specified by the Administrator during which an Award of Restricted Stock shall be subject to restrictions. 

2.40 “Securities Act” shall mean the Securities Act of 1933, as amended. 

2.41 “Share Limit” shall have the meaning provided in Section 3.1(a) hereof. 

2.42 “Shares” shall mean shares of Common Stock. 

2.43 “Stock Appreciation Right” shall mean a stock appreciation right granted under Article X hereof. 

2.44 “Stock Payment” shall mean a payment in the form of Shares awarded under Section 9.3 hereof. 

2.45 “Subsidiary” shall mean any entity (other than the Company), whether domestic or foreign, in an unbroken chain of
entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing more than fifty percent (50%) of the total
combined voting power of all classes of securities or interests in one of the other entities in such chain. 
 2.46
“Substitute Award” means any Award granted in assumption of, or in substitution for, an award of a company or business (that is not, prior to the applicable transaction, a Subsidiary or Affiliate of the Company) acquired by the
Company or a Subsidiary or Affiliate or with which the Company or a Subsidiary or Affiliate combines. 
 2.47
“Termination of Employment” shall mean, unless otherwise provided in the Award Agreement, the termination of the applicable Participant’s employment with, or performance of services for, the Company and any of its Subsidiaries
or Affiliates. Unless otherwise determined by the Committee, a Participant employed by, or performing services for, a Subsidiary or an Affiliate or a division of the Company or its Affiliates shall be deemed to incur a Termination of Employment if,
as a result of a Disaffiliation, such Subsidiary, Affiliate, or division ceases to be a Subsidiary, Affiliate or division, as the case may be, and the Participant does not immediately become an employee of, or service provider for, the Company or
another Subsidiary or Affiliate. Temporary absences from employment because of illness, vacation, or 

  
 7 

 
leave of absence, and transfers among the Company and its Subsidiaries and Affiliates, shall not be considered Terminations of Employment. Notwithstanding the foregoing, with respect to any Award
that constitutes “nonqualified deferred compensation” within the meaning of Section 409A of the Code, “Termination of Employment” shall mean a “separation from service” as defined under Section 409A of the
Code. 
 2.48 “Vesting Period” shall mean the period of time before unrestricted Shares become non-forfeitable
and issuable to a Participant pursuant to the applicable Award Agreement. 
 ARTICLE III 

SHARES SUBJECT TO THE PLAN 
 3.1 Number of Shares. 
 (a) Subject to Sections 3.2 hereof, the maximum
aggregate number of Shares available for issuance under the Plan (the “Share Limit”) shall be equal shall be equal to five percent (5%) of the number of all outstanding Shares as of the Effective Date. Notwithstanding the generality
of the foregoing, subject to Sections 3.2 hereof, the maximum number of Shares available for issuance under the Plan with respect to Incentive Stock Options shall be the number of Shares that is equal to fifty percent (50%) of the Share Limit.
Any Shares granted in connection with Options and Stock Appreciation Rights shall be counted against this limit as one (1) Share for every one (1) Option or Stock Appreciation Right awarded. Any Shares granted in connection with Awards
other than Options and Stock Appreciation Rights shall be counted against this limit as one (1) Share for every one (1) Share granted in connection with such Award or by which the Award is valued by reference. 

(b) Shares issued under the Plan may, in whole or in part, be authorized but unissued Shares or Shares that shall have been or may be
reacquired by the Company in the open market, in private transactions, or otherwise. If any Shares subject to an Award are forfeited, cancelled, exchanged or surrendered or if an Award otherwise terminates or expires without a distribution of Shares
to the Participant, the Shares with respect to such Award shall, to the extent of any such forfeiture, cancellation, exchange, surrender, termination or expiration, again be available for Awards under the Plan. Notwithstanding the foregoing, Shares
surrendered or withheld as payment of either the exercise price of an Award and/or withholding taxes in respect of an Award shall no longer be available for grant under the Plan. In addition, in the case of any Substitute Award, Shares delivered or
deliverable in connection with such Substitute Award shall not be deemed granted or issued under the Plan for purposes of Sections 3.1 or 3.3. 
 3.2 Adjustments. 
 (a) In the event of any stock dividend, stock split,
combination or exchange of Shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, amalgamation, consolidation, reclassification, recapitalization, spin-off, spin-out, repurchase or
other reorganization or corporate transaction or 

  
 8 

 
event, or any other change affecting the Shares or the Share price (any such occurrence or event, a “Change in Capitalization”), the Administrator shall make equitable adjustments, if
any, to reflect such change with respect to (i) the aggregate number and kind of Shares that may be issued under the Plan (including, but not limited to, adjustments of the Share Limit and Individual Award Limits); (ii) the number and kind
of Shares (or other securities or property) subject to outstanding Awards; (iii) the terms and conditions of any outstanding Awards (including, without limitation, any applicable performance targets or criteria with respect thereto); and/or
(iv) the grant or exercise price per Share for any outstanding Awards under the Plan; provided, however, that the Administrator shall make such equitable adjustments as it determines to be appropriate and equitable, in its sole discretion, to
prevent dilution or enlargement of rights. Without limiting the generality of the foregoing, in connection with a Change in Capitalization, the Administrator may provide, in its sole discretion, for the cancellation of any outstanding Award granted
hereunder in exchange for payment in cash or other property having an aggregate Fair Market Value of the Shares covered by such award, reduced by the aggregate exercise price or purchase price thereof, if any. In the case where the exercise price
per Share of an Option or Stock Appreciation Right exceeds the Fair Market Value per Share, the Administrator may cancel, in its sole discretion, such Option or Stock Appreciation Right for no payment. The Administrator’s determinations
pursuant to this Section 3.2(a) shall be final, binding and conclusive. 
 (b) Any adjustment affecting an Award intended
as Performance-Based Compensation shall be made consistent with the requirements of Section 162(m) of the Code unless otherwise determined by the Administrator. No action shall be taken under this Section 3.2(b) which shall cause an Award
to fail to comply with Section 409A of the Code or an exemption therefrom, in either case, to the extent applicable to such Award. 
 3.3 Individual Award Limits. Notwithstanding any provision in the Plan to the contrary, and subject to Section 3.2, to the extent required to comply with Section 162(m): 

(a) the aggregate number of Shares subject to Options and Stock Appreciation Rights awarded to any one Participant during any calendar
year may not exceed 1.5 million Shares; 
 (b) the aggregate number of Shares subject to Awards other than Options and
Stock Appreciation Rights (excluding Awards referenced in Section 3.3(c) below) awarded to any one Participant during any calendar year may not exceed 1.5 million Shares; 

(c) the aggregate amount of compensation to be paid to any one Participant in respect to all Awards that are intended to constitute
Performance-Based Compensation denominated in cash in any calendar year is $10 million; and 
 (d) the aggregate grant date
fair value (computed as of the date of grant in accordance with applicable financial accounting rules) of all Awards granted to any Director during any single calendar year shall not exceed $500,000. 

  
 9 

 ARTICLE IV 
 GRANTING OF AWARDS 
 4.1 Participation. The Committee may,
from time to time, select from among all Eligible Individuals, those to whom one or more Awards shall be granted and shall determine the nature and amount of each Award, which shall not be inconsistent with the requirements of the Plan. No Eligible
Individual shall have any right to be granted an Award pursuant to the Plan. 
 4.2 Award Agreement. Each Award shall be
evidenced by an Award Agreement stating the terms and conditions applicable to such Award, consistent with the requirements of the Plan. 
 4.3 Stand-Alone and Tandem Awards. Awards granted pursuant to the Plan may, in the sole discretion of the Administrator, be granted either alone, in addition to or in tandem with, any other Award
granted pursuant to the Plan. Awards granted in addition to or in tandem with other Awards may be granted either at the same time as or at a different time from the grant of such other Awards. 

ARTICLE V 

PROVISIONS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS PERFORMANCE-BASED COMPENSATION 

5.1 Purpose. The Committee, in its sole discretion, may determine whether any Award is intended to qualify as Performance-Based
Compensation. If the Committee, in its sole discretion, decides to grant an Award to an Eligible Individual that is intended to qualify as Performance-Based Compensation, then the provisions of this Article V shall control over any contrary
provision contained in the Plan. The Administrator may in its sole discretion grant Awards to Eligible Individuals that are based on Performance Goals but that do not satisfy the requirements of this Article V and that are not intended to qualify as
Performance-Based Compensation. 
 5.2 Payment of Performance-Based Awards. Performance Awards shall
be paid, unless otherwise determined by the Committee, no later than 2  1/2 months after the tax year in which the Performance Award vests, consistent with the requirements of Section 409A of
the Code. Unless otherwise provided in the applicable Performance Goals or Award Agreement, a Participant shall be eligible to receive payment pursuant to such Awards for a Performance Period only if and to the extent the Performance Goals for such
applicable Performance Period are achieved. The achievement of each Performance Goal shall be (i) determined in accordance with Applicable Accounting Standards, to the extent applicable and (ii) for all Awards intended to qualify as
Performance-Based Compensation, certified in accordance with the requirements of Section 162(m) of the Code. 
 5.3
Additional Limitations. Notwithstanding any other provision of the Plan and except as otherwise determined by the Committee, any Award which is granted to an Eligible Individual and is intended to qualify as Performance-Based Compensation
shall be 

  
 10 

 
subject to any additional limitations imposed under Section 162(m) of the Code that are requirements for qualification as Performance-Based Compensation, and the Plan and the Award Agreement
shall be deemed amended to the extent necessary to conform to such requirements. Determinations by the Committee in respect of all Awards intended to qualify as Performance-Based Compensation shall be made within the time prescribed by, and
otherwise in compliance with, Section 162(m) of the Code, and payment in respect of such Awards may be decreased, but not increased, in the discretion of the Committee. 
 ARTICLE VI 
 OPTIONS 

6.1 Granting of Options to Eligible Individuals. The Administrator is authorized to grant Options to Eligible Individuals from
time to time, in its sole discretion, on such terms and conditions as it may determine which shall not be inconsistent with the Plan. 
 6.2 Eligibility for Incentive Stock Options. No Incentive Stock Option shall be granted to any individual who is not an Employee of the Company or any “parent corporation” or
“subsidiary corporation” of the Company (as defined in Sections 424(e) and 424(f) of the Code, respectively). 
 6.3
Option Exercise Price. The exercise price per Share subject to each Option shall be set by the Administrator, but shall not be less than one hundred percent (100%) of the Fair Market Value of a Share on the date the Option is granted
(or, as to Incentive Stock Options, on the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). In addition, in the case of Incentive Stock Options granted to a Greater Than 10% Stockholder, such price
shall not be less than one hundred ten percent (110%) of the Fair Market Value of a Share on the date the Option is granted (or the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code). 

6.4 Option Term. The term of each Option shall be set forth in the Award Agreement; provided, however, that the term shall not be
more than ten (10) years from the date the Option is granted, or five (5) years from the date an Incentive Stock Option is granted to a Greater Than 10% Stockholder. The Award Agreement shall set forth the time period, including the time
period following a Termination of Employment, during which the Participant has the right to exercise the vested Options, which time period may not extend beyond the stated term of the Option. Except as limited by the requirements of
Section 409A or Section 422 of the Code, the Administrator may extend the term of any outstanding Option, and may extend the time period during which vested Options may be exercised, and, subject to Section 13.1 hereof, may amend any
other term or condition of such Option relating to a Termination of Employment. 
 6.5 Option Vesting. 

(a) The terms and conditions pursuant to which an Option vests in the Participant and becomes exercisable shall be set forth in the
applicable Award Agreement. Such vesting may be based on service with the Company or any Affiliate, attainment of one or more of the Performance Goals, or any other criteria selected by the Administrator. At any time after the

  
 11 

 
grant of an Option, the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects, accelerate the vesting of the Option, including following a Termination
of Employment; provided, that in no event shall an Option become exercisable following its expiration, termination or forfeiture. 
 (b) No portion of an Option which is unexercisable at a Participant’s Termination of Employment shall thereafter become exercisable, except as may be otherwise provided in the applicable Award
Agreement or by action of the Administrator following the grant of the Option. 
 6.6 Treatment of Options upon Certain
Events. The applicable Award Agreement shall provide for the treatment of each Option upon a Termination of Employment. 

6.7 Substitution of Stock Appreciation Rights. The Administrator may, in its sole discretion, substitute an Award of Stock
Appreciation Rights for an outstanding Option at any time prior to or upon exercise of such Option; provided, however, that such Stock Appreciation Rights shall be exercisable with respect to the same number of Shares for which such substituted
Option would have been exercisable, and shall also have the same exercise price and remaining term as the substituted Option. 

6.8 Partial Exercise of Options. An exercisable Option may be exercised in whole or in part. However, an Option shall not be
exercisable with respect to fractional Shares and the Administrator may require that, by the terms of the Option, a partial exercise must be with respect to a minimum number of Shares. 

6.9 Manner of Exercise of Options. A Participant may exercise an exercisable Option, subject to applicable
requirements, by paying the full exercise price and applicable withholding taxes to the stock administrator of the Company for the Shares with respect to which the Option, or portion thereof, is exercised, in one or more of the following manners:
(i) cash or check, (ii) Shares (including, in the case of payment of the exercise price of an Option, Shares issuable pursuant to the exercise of the Option), in each case, having a Fair Market Value on the date of delivery equal to the
aggregate payments required, or (iii) other form of legal consideration acceptable to the Administrator (including cashless exercise via a broker). Notwithstanding any other provision of the Plan to the contrary, no Participant who is a
Director or an “executive officer” of the Company within the meaning of Section 13(k) of the Exchange Act shall be permitted to make payment with respect to any Awards granted under the Plan, or continue any extension of credit with
respect to such payment, with a loan from the Company or a loan arranged by the Company in violation of Section 13(k) of the Exchange Act. 
 6.10 Notification Regarding Disposition. The Participant shall give the Company prompt written or electronic notice of any disposition of Shares acquired by exercise of an Incentive Stock Option
which occurs within (a) two (2) years from the date of granting (including the date the Option is modified, extended or renewed for purposes of Section 424(h) of the Code) such Option to such Participant, or (b) one (1) year
after the transfer of such Shares to such Participant. 

  
 12 

 ARTICLE VII 
 RESTRICTED STOCK 
 7.1 Award of Restricted Stock. 

(a) The Administrator is authorized to grant Restricted Stock to Eligible Individuals, and shall determine the terms and conditions,
including the restrictions, applicable to each award of Restricted Stock, which terms and conditions shall be set forth in the Award Agreement and shall not be inconsistent with the Plan, and may impose such conditions on the issuance of such
Restricted Stock as it deems appropriate. 
 (b) The Award Agreement shall set forth the purchase price, if any, and form of
payment for Restricted Stock; provided, however, that if a purchase price is charged, such purchase price shall be no less than the par value of the Shares to be purchased, unless otherwise permitted by applicable law. In all cases, legal
consideration shall be required for each issuance of Restricted Stock to the extent required by applicable law. 
 (c) The
Award Agreement shall set forth the treatment of each Award of Restricted Stock upon a Termination of Employment. 
 7.2
Rights as Stockholders. Upon issuance of Restricted Stock, the Participant shall have, unless otherwise provided herein or in the Award Agreement, all the rights of a stockholder with respect to said Shares. This includes, but is not limited
to, the right to vote Shares of Restricted Stock as the record owner thereof, and the right to receive dividends and other distributions payable to an Eligible Individual during the restriction period; provided, however, that, the Award Agreement
may provide that any distributions with respect to the Shares shall be subject to the restrictions set forth in Section 7.3 hereof. 
 7.3 Restrictions. All Shares of Restricted Stock (including any Shares received by Participants thereof with respect to Shares of Restricted Stock as a result of a Change in Capitalization) shall
be subject to restrictions and vesting requirements as set forth in the Award Agreement. Such restrictions may include, without limitation, restrictions concerning voting rights and transferability. Such restrictions may lapse separately or in
combination at such times and pursuant to such circumstances or based on such criteria as set forth in the Award Agreement, including, without limitation, criteria based on the Participant’s duration of employment or directorship with the
Company, the Performance Goals, Company or Affiliate performance, individual performance or other criteria set forth in the Award Agreement. Restricted Stock may not be sold or encumbered until all restrictions are terminated or expire. 

7.4 Restriction Period. All Shares of Restricted Stock shall have a Restriction Period of not less than three (3) years,
which may include pro-rata lapsing of restrictions thereon. Notwithstanding the foregoing, Awards covering up to five (5) percent of the total number of Shares that may be issued or delivered under the Plan and any Awards made in respect of or
in substitution for Pfizer Inc. equity awards, may contain no restrictions or be subject to a Restriction Period of less than three (3) years. 

  
 13 

 7.5 Certificates for Restricted Stock. Restricted Stock granted pursuant to the Plan
may be evidenced in such manner as the Administrator shall determine. Certificates or book entries evidencing Shares of Restricted Stock must include an appropriate legend referring to the terms, conditions, and restrictions applicable to such
Restricted Stock, and the Company may, in it sole discretion, retain physical possession of any stock certificate until such time as all applicable restrictions lapse. 
 7.6 Section 83(b) Election. If a Participant makes an election under Section 83(b) of the Code to be taxed with respect to the Restricted Stock as of the date of transfer of the
Restricted Stock rather than as of the date or dates upon which the Participant would otherwise be taxable under Section 83(a) of the Code, the Participant shall be required to deliver a copy of such election to the Company promptly after
filing such election with the Internal Revenue Service. 
 ARTICLE VIII 

RESTRICTED STOCK UNITS 
 8.1 Award of Restricted Stock Units. 
 (a) The Administrator is authorized
to grant Restricted Stock Units to Eligible Individuals, and shall determine the terms and conditions, including the restrictions, applicable to each award of Restricted Stock Units, which terms and conditions shall be set forth in the Award
Agreement and shall not be inconsistent with the Plan, and may impose such conditions on the issuance of such Restricted Stock Units as it deems appropriate. The Award Agreement shall set forth the time and form of payment of each Award of
Restricted Stock Units. 
 (b) All Restricted Stock Units shall have a Vesting Period of not less than three (3) years,
which may include pro-rata lapsing of restrictions thereon. Notwithstanding the foregoing, Awards covering up to five (5) percent of the total number of Shares that may be issued or delivered under the Plan and any Awards made in respect of or
in substitution for Pfizer Inc. equity awards, may contain no restrictions or be subject to a Vesting Period of less than three (3) years. 
 (c) The Administrator shall specify, or permit the Participant to elect, the conditions and dates upon which the Shares underlying the Restricted Stock Units shall be issued (or cash in lieu thereof shall
be paid), which dates shall not be earlier than the date as of which the Restricted Stock Units vest and become nonforfeitable. Such conditions and dates shall be established in accordance with the applicable provisions of Section 409A of the
Code or an exemption therefrom. 
 (d) The Award Agreement shall set forth the treatment of each Award of Restricted Stock
Units upon a Termination of Employment. 
 (e) On the distribution dates, the Company shall issue to the Participant one
unrestricted, fully transferable Share (or if provided in the Award Agreement, the Fair Market Value of one such Share in cash) for each vested and nonforfeitable Restricted Stock Unit. 

  
 14 

 ARTICLE IX 
 PERFORMANCE AWARDS, DIVIDEND EQUIVALENTS, STOCK PAYMENTS, OTHER INCENTIVE AWARDS 
 9.1 Performance Awards. 
 (a) The Administrator is authorized to grant
Performance Awards to any Eligible Individual and to determine whether such Performance Awards shall be Performance-Based Compensation per Article V of this Plan. The vesting and value of Performance Awards may be linked to any one or more of the
Performance Goals or other specific criteria determined by the Administrator, in each case on a specified date or dates or over any period or periods as set forth in the applicable Award Agreement. Performance Awards may be paid in cash, Shares or a
combination of both. 
 (b) Without limiting Section 9.1(a) hereof, the Administrator may grant Performance Awards to any
Eligible Individual in the form of a cash bonus payable upon the attainment of objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each case on a specified date or dates or
over any period or periods determined by the Administrator. Any such cash bonuses paid to a Participant which are intended to be Performance-Based Compensation shall be based upon objectively determinable bonus formulas established in accordance
with the provisions of Article V hereof. 
 9.2 Dividend Equivalents. 

(a) Subject to Section 9.2(b) hereof, Dividend Equivalents may be granted by the Administrator, either alone or in tandem with
another Award, based on dividends declared on the Common Stock, to be credited as of dividend payment dates during the period between the date the Dividend Equivalents are granted to a Participant and the date such Dividend Equivalents terminate or
expire, as determined by the Administrator. Such Dividend Equivalents shall be converted to cash or additional Shares by such formula, at such time and subject to such limitations as set forth in the applicable Award Agreement. In addition, the
Award Agreement may provide that Dividend Equivalents with respect to Shares covered by an Award shall only be paid out to the Participant at the same time or times and to the same extent that the vesting conditions and/or performance goals, if any,
are subsequently satisfied and the Award vests with respect to such Shares. 
 (b) Notwithstanding the foregoing, no Dividend
Equivalents shall be payable with respect to Options or Stock Appreciation Rights, unless otherwise determined by the Administrator. 
 9.3 Stock Payments. The Administrator is authorized to make one or more Stock Payments to any Eligible Individual. The number or value of Shares of any Stock Payment shall be determined by the
Administrator and may be based upon one or more Performance Goals or any other specific criteria, including service to the Company or any Affiliate, determined by the Administrator. 

  
 15 

 9.4 Other Incentive Awards. The Administrator is authorized to grant Other Incentive
Awards to any Eligible Individual, which Awards may cover Shares or the right to purchase Shares or have a value derived from the value of, or an exercise or conversion privilege at a price related to, or that are otherwise payable in or based on,
Shares, stockholder value or stockholder return, in each case, on a specified date or dates or over any period or periods determined by the Administrator. The terms and conditions applicable to such Other Incentive Awards shall be set forth in the
applicable Award Agreement. Other Incentive Awards may be linked to any one or more of the Performance Goals or other specific criteria determined appropriate by the Administrator and may be payable in cash or Shares. 

9.5 Other Terms and Conditions. All applicable terms and conditions of each Award described in this Article IX, including without
limitation, as applicable, the term, vesting conditions and exercise/purchase price applicable to the Award, shall be set by the Administrator in its sole discretion, provided, however, that the value of the consideration paid by a Participant for
an Award shall not be less than the par value of a Share, unless otherwise permitted by applicable law. The rights of Participants granted Performance Awards, Dividend Equivalents, or Other Incentive Awards upon Termination of Employment shall be
set forth in the Award Agreement. 
 ARTICLE X 
 STOCK APPRECIATION RIGHTS 
 10.1 Grant of Stock Appreciation
Rights. 
 (a) The Administrator is authorized to grant Awards of Stock Appreciation Rights to Eligible Individuals from
time to time, in its sole discretion, on such terms and conditions as it may determine consistent with the Plan. 
 (b) Each
Award of Stock Appreciation Rights shall entitle the Participant (or other individual entitled to exercise the Award of Stock Appreciation Rights pursuant to the Plan) to exercise all or a specified portion of the Award of Stock Appreciation Rights
(to the extent then exercisable pursuant to its terms) and to receive from the Company an amount determined by multiplying the difference obtained by subtracting the exercise price per Share of the Stock Appreciation Rights from the Fair Market
Value on the date of exercise of the Stock Appreciation Right by the number of Stock Appreciation Rights that shall have been exercised, subject to any limitations the Administrator may impose or set forth in the Award Agreement. Such amount shall
be payable in Shares or in cash, as determined by the Administrator. The exercise price per Share subject to each Award of Stock Appreciation Rights shall be set by the Administrator, but shall not be less than one hundred percent (100%) of the
Fair Market Value on the date the Stock Appreciation Rights are granted. 
 (c) The Award Agreement shall set forth the
treatment of each Award of Stock Appreciation Rights upon a Termination of Employment. 

  
 16 

 10.2 Stock Appreciation Right Vesting. 

(a) The Award Agreement shall set forth the period during which a Participant shall vest in an Award of Stock Appreciation Rights and
have the right to exercise such Stock Appreciation Rights (subject to Section 10.4 hereof) in whole or in part. Such vesting may be based on service with the Company or any Affiliate, any of the Performance Goals or any other criteria selected
by the Administrator. At any time after grant of an Award of Stock Appreciation Rights, the Administrator may, in its sole discretion and subject to whatever terms and conditions it selects, accelerate the period during which the Stock Appreciation
Rights vest. 
 (b) No portion of an Award of Stock Appreciation Rights which is unexercisable upon Termination of Employment
shall thereafter become exercisable, except as may be otherwise provided in an Award Agreement or by action of the Administrator following the grant of the Stock Appreciation Rights; provided, that in no event shall an Award of Stock Appreciation
Rights become exercisable following its expiration, termination or forfeiture. 
 10.3 Manner of Exercise. A Participant
may exercise an exercisable Stock Appreciation Right as follows, subject to applicable requirements established by the Administrator; full payment of the applicable withholding taxes shall be made to the stock administrator of the Company for the
Shares with respect to which the Stock Appreciation Rights, or portion thereof, are exercised, in a manner permitted by Section 6.9 in respect of Options. 
 10.4 Stock Appreciation Right Term. The term of each Award of Stock Appreciation Rights shall be set forth in the Award Agreement; provided, however, that the term shall not be more than ten
(10) years from the date the Stock Appreciation Rights are granted. The Award Agreement shall set forth the time period, including any time period following a Termination of Employment, during which the Participant has the right to exercise any
vested Stock Appreciation Rights, which time period may not extend beyond the expiration date of the Award term. Except as limited by the requirements of Section 409A of the Code, the Administrator may extend the term of any outstanding Stock
Appreciation Rights, and may extend the time period during which vested Stock Appreciation Rights may be exercised in connection with any Termination of Employment, and, subject to Section 13.1 hereof, may amend any other term or condition of
such Stock Appreciation Rights relating to such a Termination of Employment. 
 ARTICLE XI 

ADDITIONAL TERMS OF AWARDS 
 11.1 Change in Control. Unless otherwise set forth in an Award Agreement, in the event of a Change in Control: 
 (a) With respect to each outstanding Award that is assumed or substituted in connection with a Change in Control, in the event the Participant incurs a Termination of Employment other than for
“cause,” as defined in the applicable Award 

  
 17 

 
Agreement, during the 24-month period following such Change in Control, on the date of such Termination of Employment (i) such Award shall become fully vested and, if applicable,
exercisable, (ii) the restrictions, payment conditions, and forfeiture conditions applicable to any such Award granted shall lapse and (iii) and any performance conditions imposed with respect to such Award shall be deemed to be achieved
at target performance levels. 
 (b) With respect to each outstanding Award that is not assumed or substituted in connection
with a Change in Control, immediately upon the occurrence of the Change in Control (i) such Award shall become fully vested and, if applicable, exercisable, (ii) the restrictions, payment conditions, and forfeiture conditions applicable to
any such Award granted shall lapse and (iii) and any performance conditions imposed with respect to such Award shall be deemed to be achieved at target performance levels. 

(c) For purposes of this Section 11.1, an Award shall be considered assumed or substituted for if, following the Change in Control,
the Award is of comparable value and remains subject to the same terms and conditions that were applicable to the Award immediately prior to the Change in Control except that, if the Award related to Shares, the Award instead confers the right to
receive common stock of the acquiring entity or in the case of an amalgamation, the amalgamated company or its parent. 
 (d)
Notwithstanding the foregoing, if any Award is subject to Section 409A of the Code, this Section 11.1 shall be applicable only to the extent specifically provided in the Award Agreement and as permitted pursuant to Section 13.5.

 11.2 Tax Withholding. The Company and its Affiliates shall have the authority and the right to deduct or withhold, or
require a Participant to remit to the Company or an Affiliate, an amount sufficient to satisfy federal, state, local and foreign taxes (including the Participant’s social security, Medicare and any other employment tax obligation) required by
law to be withheld with respect to any taxable event concerning a Participant arising in connection with any Award. The Administrator may in its sole discretion and in satisfaction of the foregoing requirement allow a Participant to elect to have
the Company or an Affiliate withhold Shares otherwise issuable under an Award (or allow the surrender of Shares), provided that the number of Shares which may be so withheld or surrendered shall be limited to the number of Shares which have a Fair
Market Value on the date of withholding no greater than the amount necessary to satisfy the minimum statutory withholding requirements. 
 11.3 Transferability of Awards. 
 (a) No Award under the Plan may be sold,
pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution; 
 (b) No Award or
interest or right therein shall be liable for the debts, contracts or engagements of the Participant or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, hypothecation, encumbrance,
assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy) unless and until such Award has
been exercised, or the 

  
 18 

 
Shares underlying such Award have been issued, and all restrictions applicable to such Shares have lapsed, and any attempted disposition of an Award prior to the satisfaction of these conditions
shall be null and void and of no effect; 
 (c) During the lifetime of the Participant, only the Participant may exercise an
Award (or any portion thereof) granted to him or her under the Plan. After the death of the Participant, any exercisable portion of an Award may, prior to the time when such portion becomes unexercisable under the Plan or Award Agreement, be
exercised by his personal representative or by any individual empowered to do so under the deceased Participant’s will or under the then-applicable laws of descent and distribution; and 

(d) Notwithstanding the foregoing, the Administrator may, in its sole discretion, permit (on such terms, conditions and limitations as it
may establish) Non-Qualified Stock Options and/or Shares issued in connection with an Option or a Stock Appreciation Right exercise that are subject to restrictions on transferability, to be transferred to a member of a Participant’s immediate
family or to a trust or similar vehicle for the benefit of a Participant’s immediate family members. 
 11.4 Conditions
to Issuance of Shares. 
 (a) Notwithstanding anything herein to the contrary, neither the Company nor its Affiliates shall
be required to issue or deliver any certificates or make any book entries evidencing Shares pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice of counsel, that the issuance of such Shares is in
compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the Shares are listed or traded, and the Shares are covered by an effective registration statement or
applicable exemption from registration. In addition to the terms and conditions provided herein, the Administrator may require that a Participant make such reasonable covenants, agreements, and representations as the Administrator, in its
discretion, deems advisable in order to comply with any laws, regulations, or requirements. 
 (b) All Share certificates
delivered pursuant to the Plan and all Shares issued pursuant to book entry procedures are subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state, or foreign
securities or other laws, rules and regulations and the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted, or traded. The Administrator may place legends on any Share certificate or book entry to
reference restrictions applicable to the Shares. 
 (c) The Administrator shall have the right to require any Participant to
comply with any timing or other restrictions with respect to the settlement, distribution or exercise of any Award, including a window-period limitation, as may be imposed in the sole discretion of the Administrator. 

  
 19 

 (d) No fractional Shares shall be issued and the Administrator shall determine, in its sole
discretion, whether cash shall be given in lieu of fractional Shares or whether such fractional Shares shall be eliminated by rounding down. 
 (e) Notwithstanding any other provision of the Plan, unless otherwise determined by the Administrator or required by any applicable law, rule or regulation, the Company and/or its Affiliates may, in lieu
of delivering to any Participant certificates evidencing Shares issued in connection with any Award, record the issuance of Shares in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). 

11.5 Forfeiture and Recoupment Provisions. Pursuant to its general authority to determine the terms and conditions applicable to
Awards under the Plan, the Administrator shall have the right to provide, in the terms of Awards made under the Plan, or to require a Participant to agree by separate written or electronic instrument, that: any proceeds, gains or other economic
benefit must be paid to the Company, and the Award shall terminate and any unexercised portion of the Award (whether or not vested) shall be forfeited, if (i) a Termination of Employment occurs prior to a specified date, or within a specified
time period following receipt or exercise of the Award, (ii) the Participant at any time, or during a specified time period, engages in any activity which violates any applicable restrictive covenants of the Company, as may be further specified
in the Award Agreement or (iii) the Participant incurs a Termination of Employment for “cause,” as defined in the applicable Award Agreement. In addition, all Awards made under the Plan shall be subject to any clawback or recoupment
policies of the Company, as in effect from time to time, or as otherwise required by law. 
 11.6 Prohibition on
Repricing. Subject to limitations imposed by Section 409A of the Code or other applicable law and the limitations contained in Section 13.1 below, in no event shall the exercise price with respect to an Award be reduced following the
grant of an Award, nor shall an Award be cancelled in exchange for a replacement Award with a lower exercise price or in exchange for another type of Award or cash payment without stockholder approval. 

11.7 Leave of Absence. Unless the Administrator provides otherwise, vesting of Awards granted hereunder shall be suspended during
any unpaid leave of absence. A Participant shall not cease to be considered an Employee or Non-Employee Director, as applicable, in the case of any (a) leave of absence approved by the Company, or (b) transfer between locations of the
Company or between the Company and any of its Affiliates or any successor thereof. 
 ARTICLE XII 

ADMINISTRATION 
 12.1 Administrator. The Committee (or another committee or a subcommittee of the Board assuming the functions of the Committee under the Plan) shall administer the Plan (except as otherwise
permitted herein) and shall be referred to herein as the “Administrator.” Unless otherwise determined by the Board, the Committee shall consist solely of two or more 

  
 20 

 
Non-Employee Directors appointed by and holding office at the pleasure of the Board, each of whom is intended to qualify as a “non-employee director” as defined by Rule 16b-3 of the
Exchange Act, an “outside director” for purposes of Section 162(m) of the Code and an “independent director” under the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or
traded, in each case, to the extent required under such provision; provided, however, that any action taken by the Committee shall be valid and effective, whether or not members of the Committee at the time of such action are later determined not to
have satisfied the requirements for membership set forth in this Section 12.l or otherwise provided in any charter of the Committee. Notwithstanding the foregoing, (a) the full Board, acting by a majority of its members in office, shall
conduct the general administration of the Plan with respect to Awards granted to Non-Employee Directors and (b) the Board or Committee may delegate its authority hereunder to the extent permitted by Section 12.5 hereof. 

12.2 Duties and Powers of Administrator. It shall be the duty of the Administrator to conduct the general administration of the
Plan in accordance with its provisions. The Administrator shall have the power to interpret the Plan and all Award Agreements, and to adopt such rules for the administration, interpretation and application of the Plan as are not inconsistent with
the Plan, to interpret, amend or revoke any such rules and to amend any Award Agreement, provided that the rights or obligations of the holder of the Award that is the subject of any such Award Agreement are not affected adversely by such amendment
unless the consent of the Participant is obtained or such amendment is otherwise permitted under Section 13.1 hereof. In its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the
Committee under the Plan except with respect to matters which under Rule 16b-3 under the Exchange Act, Section 162(m) of the Code, or the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or
traded are required to be determined in the sole discretion of the Committee. 
 12.3 Authority of Administrator. Subject
to any specific designation in the Plan, the Administrator has the exclusive power, authority and sole discretion to: 
 (a)
Designate Eligible Individuals to receive Awards; 
 (b) Determine the type or types of Awards to be granted to Eligible
Individuals; 
 (c) Determine the number of Awards to be granted and the number of Shares to which an Award will relate;

 (d) Determine the terms and conditions of any Award granted pursuant to the Plan, including, but not limited to, the
exercise price, grant price, or purchase price, any performance criteria, any restrictions or limitations on the Award, any schedule for vesting, lapse of forfeiture restrictions or restrictions on the exercisability of an Award, and accelerations
or waivers thereof, and any provisions related to non-competition and recapture of gain on an Award, based in each case on such considerations as the Administrator in its sole discretion determines; 

  
 21 

 (e) Determine whether, to what extent, and pursuant to what circumstances an Award may be
settled in, or the exercise price of an Award may be paid in cash, Shares, other Awards, or other property, or an Award may be canceled, forfeited, or surrendered; 
 (f) Prescribe the form of each Award Agreement, which need not be identical for each Participant; 
 (g) Decide all other matters that must be determined in connection with an Award; 

(h) Establish, adopt, or revise any rules and regulations as it may deem necessary or advisable to administer the Plan; 

(i) Interpret the terms of, and any matter arising pursuant to, the Plan or any Award Agreement; and 

(j) Make all other decisions and determinations that may be required pursuant to the Plan or as the Administrator deems necessary or
advisable to administer the Plan. 
 12.4 Decisions Binding. The Administrator’s interpretation of the Plan, any
Awards granted pursuant to the Plan or any Award Agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. 

12.5 Delegation of Authority. To the extent permitted by applicable law or the rules of any securities exchange or automated
quotation system on which the Shares are listed, quoted or traded, the Board or Committee may from time to time delegate to a committee of one or more members of the Board, to one or more officers of the Company the authority to grant or amend
Awards or to take other administrative actions pursuant to this Article XII; provided, however, that in no event shall an officer of the Company be delegated the authority to grant Awards to, or amend Awards held by, the following individuals:
(a) individuals who are subject to Section 16 of the Exchange Act, (b) Covered Employees with respect to Awards intended to constitute Performance-Based Compensation, or (c) officers of the Company (or Directors) to whom
authority to grant or amend Awards has been delegated hereunder; provided further, that any delegation of administrative authority shall only be permitted to the extent it is permissible under Section 162(m) of the Code and applicable
securities laws or the rules of any securities exchange or automated quotation system on which the Shares are listed, quoted or traded. Any delegation hereunder shall be subject to the restrictions and limits that the Board or Committee specifies at
the time of such delegation, and the Board may at any time rescind the authority so delegated or appoint a new delegatee. At all times, the delegatee appointed under this Section 12.5 shall serve in such capacity at the pleasure of the Board
and the Committee. 

  
 22 

 ARTICLE XIII 
 MISCELLANEOUS PROVISIONS 
 13.1 Amendment, Suspension or
Termination of the Plan. The Plan may be amended or terminated at any time by action of the Board. However, no amendment may, without stockholder approval, except as set forth in Section 3.2 herein, (i) increase the aggregate number of
Shares available for Awards, (ii) extend the term of the Plan, (iii) materially expand the types of awards available under the Plan, (iv) change the definition of Eligible Individual to add a category or categories of individuals who
are eligible to participate in the Plan, (v) delete or limit the prohibition against repricing of Awards contained in Section 11.6, or (vi) make other changes which require approval by the stockholders of the Company in order to
comply with applicable law or applicable stock market rules. No amendment or termination of the Plan may adversely modify any individual’s rights under an outstanding Award unless such individual consents to the modification in writing.

 13.2 Paperless Administration. In the event that the Company establishes, for itself or using the services of a third
party, an automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Participant may be
permitted through the use of such an automated system. 
 13.3 Titles and Headings, References to Sections of the Code or
Exchange Act. The titles and headings of the sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control. References to sections of the
Code or the Exchange Act shall include any amendment or successor thereto. 
 13.4 Governing Law. The Plan and any
programs and agreements hereunder shall be administered, interpreted and enforced under the internal laws of the State of Delaware without regard to conflicts of laws thereof. 
 13.5 Section 409A. The intent of the parties is that payments and benefits under the Plan comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the
maximum extent permitted, the Plan shall be interpreted and be administered to be in compliance therewith. Any payments described in the Plan that are due within the “short-term deferral period” as defined in Section 409A of the Code
shall not be treated as deferred compensation unless applicable law requires otherwise. Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under
Section 409A of the Code, the Participant shall not be considered to have terminated employment with the Company for purposes of the Plan and no payment shall be due to the Participant under the Plan or any Award until the Participant would be
considered to have incurred a “separation from service” from the Company within the meaning of Section 409A of the Code. Notwithstanding anything to the contrary in the Plan, to the extent required in order to avoid accelerated
taxation and/or tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the
Participant’s Termination of 

  
 23 

 
Employment shall instead be paid on the first business day after the date that is six (6) months following the Participant’s separation from service (or upon the Participant’s
death, if earlier). In addition, for purposes of the Plan, each amount to be paid or benefit to be provided to the Participant pursuant to the Plan, which constitute deferred compensation subject to Section 409A of the Code, shall be construed
as a separate identified payment for purposes of Section 409A of the Code. 
 13.6 No Rights to Awards. No Eligible
Individual or other individual shall have any claim to be granted any Award pursuant to the Plan, and neither the Company nor the Administrator is obligated to treat Eligible Individuals, Participants or any other individuals uniformly. 

13.7 Foreign Employees and Foreign Law Considerations. The Administrator may grant Awards to Eligible Individuals who are foreign
nationals, who are located outside the United States, who are United States citizens or resident aliens on global assignments in foreign nations, who are not compensated from a payroll maintained in the United States, or who are otherwise subject to
(or could cause the Company to be subject to) legal or regulatory provisions of countries or jurisdictions outside the United States, on such terms and conditions different from those specified in the Plan as may, in the judgment of the
Administrator, be necessary or desirable to foster and promote achievement of the purposes of the Plan, and, in furtherance of such purposes, the Administrator may make such modifications, amendments, procedures, or subplans as may be necessary or
advisable to comply with such legal or regulatory provisions. 
 13.8 Unfunded Status of Awards. The Plan is intended to
be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or Award Agreement shall give the Participant any rights that are greater than
those of a general creditor of the Company or any Affiliate. 
 13.9 Indemnification. To the extent allowable pursuant to
applicable law, each member of the Board and any officer or other employee to whom authority to administer any component of the Plan is delegated shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that
may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action or failure to act
pursuant to the Plan and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; provided, however, that he or she gives the Company an opportunity, at its own
expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such individuals may
be entitled pursuant to the Company’s Certificate of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless. 

13.10 Relationship to other Benefits. No payment pursuant to the Plan shall be taken into account in determining any benefits
under any pension, retirement, savings, profit sharing, group insurance, welfare, or other benefit plan of the Company or any Affiliate except to the extent otherwise expressly provided in writing in such other plan or an agreement thereunder.

  
 24 

 13.11 Successors. The obligations of the Company under the Plan shall be binding upon
any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company.

 13.12 Expenses. The expenses of administering the Plan shall be borne by the Company and its Affiliates. 

13.13 Term of Plan. The Plan shall terminate on the tenth anniversary of the Effective Date; provided, however, any Awards that
are outstanding as of the date of the Plan’s termination shall remain in effect, and the terms of the Plan shall apply until such Awards terminate as provided in the applicable Award Agreements. 

  
 25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]